IL93983A - Method for enhanced transmembrane transport of exogenous molecules - Google Patents

Method for enhanced transmembrane transport of exogenous molecules

Info

Publication number
IL93983A
IL93983A IL9398390A IL9398390A IL93983A IL 93983 A IL93983 A IL 93983A IL 9398390 A IL9398390 A IL 9398390A IL 9398390 A IL9398390 A IL 9398390A IL 93983 A IL93983 A IL 93983A
Authority
IL
Israel
Prior art keywords
transmembrane transport
exogenous molecules
folate
enhanced transmembrane
enhanced
Prior art date
Application number
IL9398390A
Other languages
English (en)
Other versions
IL93983A0 (en
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of IL93983A0 publication Critical patent/IL93983A0/xx
Publication of IL93983A publication Critical patent/IL93983A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8206—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation by physical or chemical, i.e. non-biological, means, e.g. electroporation, PEG mediated
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Optics & Photonics (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Tents Or Canopies (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Wrappers (AREA)
IL9398390A 1989-04-03 1990-04-02 Method for enhanced transmembrane transport of exogenous molecules IL93983A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33181689A 1989-04-03 1989-04-03
US07/498,762 US5108921A (en) 1989-04-03 1990-03-28 Method for enhanced transmembrane transport of exogenous molecules

Publications (2)

Publication Number Publication Date
IL93983A0 IL93983A0 (en) 1991-01-31
IL93983A true IL93983A (en) 1997-02-18

Family

ID=26987937

Family Applications (1)

Application Number Title Priority Date Filing Date
IL9398390A IL93983A (en) 1989-04-03 1990-04-02 Method for enhanced transmembrane transport of exogenous molecules

Country Status (13)

Country Link
US (4) US5108921A (de)
EP (1) EP0466816B1 (de)
JP (1) JP3232347B2 (de)
AT (1) ATE160583T1 (de)
AU (1) AU5437590A (de)
CA (2) CA2013582C (de)
DE (1) DE69031763T2 (de)
DK (1) DK0466816T3 (de)
ES (1) ES2113346T3 (de)
IE (1) IE81171B1 (de)
IL (1) IL93983A (de)
PT (1) PT93646A (de)
WO (1) WO1990012096A1 (de)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10500204B2 (en) 2007-06-25 2019-12-10 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10647676B2 (en) 2004-07-23 2020-05-12 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10738086B2 (en) 2007-06-25 2020-08-11 Endocyte Inc. Conjugates containing hydrophilic spacer linkers
US10765756B2 (en) 2012-02-24 2020-09-08 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy

Families Citing this family (862)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643889A (en) * 1984-07-11 1997-07-01 Temple University-Of The Commonwealth System Of Pennsylvania Cholesterol conjugates of 2'5'-oligoadenylate derivatives and antiviral uses thereof
US5550111A (en) * 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
US5688488A (en) * 1989-04-03 1997-11-18 Purdue Research Foundation Composition and method for tumor imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US6395492B1 (en) * 1990-01-11 2002-05-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US7037646B1 (en) 1990-01-11 2006-05-02 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6114513A (en) 1990-01-11 2000-09-05 Isis Pharmaceuticals, Inc. Thiol-derivatized oligonucleotides
US6153737A (en) * 1990-01-11 2000-11-28 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
JPH06510278A (ja) * 1991-06-05 1994-11-17 ユニバーシティ オブ コネチカット 分泌タンパク質をコードする遺伝子の標的への配達
US6287792B1 (en) * 1991-06-17 2001-09-11 The Regents Of The University Of California Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
US5981273A (en) * 1991-09-30 1999-11-09 Boehringer Ingelheim Int'l. Gmbh Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
US5254342A (en) * 1991-09-30 1993-10-19 University Of Southern California Compositions and methods for enhanced transepithelial and transendothelial transport or active agents
NZ244306A (en) * 1991-09-30 1995-07-26 Boehringer Ingelheim Int Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
US6831166B2 (en) 1992-10-23 2004-12-14 Isis Pharmaceuticals, Inc. Derivatized oligonucleotides having improved uptake and other properties
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
EP0632722A4 (de) * 1992-03-20 1997-07-30 Baylor College Medicine In form-imc-beschichtungsverfahren mit doppelaushaertung zur herstellung von abriebfesten,beschichteten,thermoplastischen gegenstaenden.
US6033884A (en) 1992-03-20 2000-03-07 Baylor College Of Medicine Nucleic acid transporter systems and methods of use
WO1994004194A1 (en) * 1992-08-14 1994-03-03 Massachusetts Institute Of Technology Nucleic acid recognition and transport
US20020173474A1 (en) * 1993-02-12 2002-11-21 President And Fellows Of Harvard College Methods & materials involving dimerization-mediated regulation of biological events
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
AU679566B2 (en) 1993-09-03 1997-07-03 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US6653458B1 (en) 1993-09-03 2003-11-25 Isis Pharmaceuticals, Inc. Modified oligonucleotides
US5635385A (en) * 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US5972901A (en) * 1994-03-23 1999-10-26 Case Western Reserve University Serpin enzyme complex receptor--mediated gene transfer
AU696455C (en) * 1994-03-23 2006-03-02 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US6077835A (en) * 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
EP0758196A4 (de) * 1994-05-05 1999-05-06 Univ Pennsylvania Zusammensetzungen und verfahren zur tumorbehandlung
US5670347A (en) 1994-05-11 1997-09-23 Amba Biosciences Llc Peptide-mediated gene transfer
JP4013996B2 (ja) * 1994-06-06 2007-11-28 テムド トラスト 腫瘍および感染部位に指向させるためのビオチン化合物
US5716594A (en) * 1994-06-06 1998-02-10 The Jmde Trust Biotin compounds for targetting tumors and sites of infection
US5837533A (en) * 1994-09-28 1998-11-17 American Home Products Corporation Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent
WO1996012501A1 (en) * 1994-10-19 1996-05-02 Human Genome Sciences, Inc. Human hypoxanthine-(guanine) phosphoribosyl transferase-2
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
EP0888128A2 (de) 1995-02-10 1999-01-07 The Worcester Foundation For Biomedical Research Abgabe von exogenen verbindungen
US5846743A (en) * 1995-02-22 1998-12-08 Brigham And Women's Hospital, Inc. Polyphoshoinositide binding peptides for intracellular drug delivery
US5674748A (en) 1995-03-14 1997-10-07 Thomas Jefferson University Human cyclin-dependent kinase-like proteins and methods of using the same
US5547668A (en) * 1995-05-05 1996-08-20 The Board Of Trustees Of The University Of Illinois Conjugates of folate anti-effector cell antibodies
US5672500A (en) 1995-05-18 1997-09-30 Thomas Jefferson University Mch2, an apoptotic cysteine protease, and compositions for making and methods of using the same
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
US5817789A (en) * 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US5912160A (en) * 1995-08-22 1999-06-15 Thomas Jefferson University Gab1, Grb2 binding protein, and compositions for making and methods of using the same
US20030119724A1 (en) * 1995-11-22 2003-06-26 Ts`O Paul O.P. Ligands to enhance cellular uptake of biomolecules
CA2279669A1 (en) * 1995-12-15 1997-06-16 Enzo Therapeutics, Inc. Property effecting and/or property exhibiting constructs for the expression of non-native nucleic acid processing components for therapeutic and diagnostic uses
US20040014709A1 (en) * 1996-01-08 2004-01-22 Canji, Inc. Methods and compositions for interferon therapy
US7002027B1 (en) 1996-01-08 2006-02-21 Canji, Inc. Compositions and methods for therapeutic use
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US5789244A (en) * 1996-01-08 1998-08-04 Canji, Inc. Compositions and methods for the treatment of cancer using recombinant viral vector delivery systems
US6392069B2 (en) 1996-01-08 2002-05-21 Canji, Inc. Compositions for enhancing delivery of nucleic acids to cells
US6180767B1 (en) 1996-01-11 2001-01-30 Thomas Jefferson University Peptide nucleic acid conjugates
US6060587A (en) 1996-01-29 2000-05-09 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 VPR essential for G2/M phase transition of the cell cycle
US5783566A (en) * 1996-05-10 1998-07-21 California Institute Of Technology Method for increasing or decreasing transfection efficiency
CA2174803C (en) * 1996-04-23 2000-07-11 Jonathan P. Wong Use of liposome encapsulated ciprofloxacin as an immunotherapeutic drug
US6261787B1 (en) 1996-06-03 2001-07-17 Case Western Reserve University Bifunctional molecules for delivery of therapeutics
WO2001008708A2 (en) * 1999-07-29 2001-02-08 Case Western Reserve University Enhanced delivery via serpin enzyme complex receptor ligands
US6072041A (en) * 1996-06-03 2000-06-06 Case Western Reserve University Fusion proteins for protein delivery
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
JPH09324000A (ja) * 1996-06-05 1997-12-16 Suntory Ltd インターロイキン−２受容体を特異的に認識する因子とリボヌクレアーゼとの接合体
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US9096636B2 (en) 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US20040171031A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20050119470A1 (en) * 1996-06-06 2005-06-02 Muthiah Manoharan Conjugated oligomeric compounds and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20050042647A1 (en) * 1996-06-06 2005-02-24 Baker Brenda F. Phosphorous-linked oligomeric compounds and their use in gene modulation
US20060002949A1 (en) * 1996-11-14 2006-01-05 Army Govt. Of The Usa, As Rep. By Secretary Of The Office Of The Command Judge Advocate, Hq Usamrmc. Transcutaneous immunization without heterologous adjuvant
WO1998020887A1 (en) * 1996-11-14 1998-05-22 Brigham And Women's Hospital, Inc. Polyphosphoinositide binding peptides for intracellular drug delivery
US6797276B1 (en) 1996-11-14 2004-09-28 The United States Of America As Represented By The Secretary Of The Army Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response
US20060002959A1 (en) * 1996-11-14 2006-01-05 Government Of The United States Skin-sctive adjuvants for transcutaneous immuization
US5980898A (en) * 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
US6942963B1 (en) 1997-01-10 2005-09-13 Massachusetts Institute Of Technology Methods for identifying treatments for neurotoxicity in Alzheimer's disease caused by β-amyloid peptides
US6172043B1 (en) 1997-01-10 2001-01-09 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's disease caused by β amyloid peptides
EP2305709A1 (de) 1997-04-09 2011-04-06 Intellect Neurosciences, Inc. Beta-Amyloid-Enden-spezifische rekombinante Antikörper, DNS-Codierung und Verwendungsverfahren
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US6037461A (en) * 1997-05-20 2000-03-14 Thomas Jefferson University FADD-like anti-apoptotic molecules, methods of using the same, and compositions for and methods of making the same
JP2002510319A (ja) 1997-07-01 2002-04-02 アイシス・ファーマシューティカルス・インコーポレーテッド オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法
ES2389519T3 (es) 1997-09-18 2012-10-26 The Trustees Of The University Of Pennsylvania Casetes de inmunización de ADN de vif atenuados para vacunas genéticas
CA2306423A1 (en) * 1997-10-14 1999-04-22 Nadine A. Tatton Methods for increasing schwann cell survival
GB9721901D0 (en) 1997-10-16 1997-12-17 Univ Manchester Particles
US20040258703A1 (en) * 1997-11-14 2004-12-23 The Government Of The Us, As Represented By The Secretary Of The Army Skin-active adjuvants for transcutaneous immunization
AU2970299A (en) * 1998-02-10 1999-08-23 Ohio State University Research Foundation, The Compositions and methods for polynucleotide delivery
US20040002079A1 (en) * 1998-02-11 2004-01-01 Gunn Robert B. Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness
US20020137786A1 (en) * 1998-02-12 2002-09-26 William G. Tatton Deprenyl compounds to treat viral infections and reduce tissue damage associated therewith
US20090011984A1 (en) * 1998-02-23 2009-01-08 Seppo Yla-Herttuala Biotin-binding receptor molecules
US6417168B1 (en) 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
US6329356B1 (en) * 1998-04-10 2001-12-11 Neurochem, Inc. Phosphono-carboxylate compounds for treating amyloidosis
US6093382A (en) 1998-05-16 2000-07-25 Bracco Research Usa Inc. Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
WO1999060012A1 (en) * 1998-05-21 1999-11-25 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6300319B1 (en) 1998-06-16 2001-10-09 Isis Pharmaceuticals, Inc. Targeted oligonucleotide conjugates
US20030219427A1 (en) * 1998-08-18 2003-11-27 Allen Hamish J. TPL-2/COT kinase and methods of use
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6448078B1 (en) 1998-10-09 2002-09-10 The Trustees Of The University Of Pennsylvania Cellular receptor for HIV-1 Vpr essential for G2/M phase transition of the cell cycle
PT1131457E (pt) 1998-11-19 2010-11-18 Univ Georgetown Sistema de transferência génica sistémica de vírus/ligandos e de terapia génica
US20050063950A1 (en) * 1998-11-19 2005-03-24 Georgetown University Systemic viral/ligand gene delivery system and gene therapy
MXPA01006201A (es) * 1998-12-18 2003-06-06 Hadasit Med Res Service Metodo para administrar un compuesto a celulas resistentes a multiples medicamentos.
US6974698B1 (en) 1999-01-15 2005-12-13 The United States Of America As Represented By The Department Of Health And Human Services Methods for delivering biologically active molecules into cells
CA2363077A1 (en) * 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
EP1165132B1 (de) * 1999-04-08 2011-10-19 Intercell USA, Inc. Trockenformulierung für transkutane immunisierung
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
GB9908195D0 (en) 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
DE60042896D1 (de) * 1999-04-28 2009-10-15 Bellus Health Int Ltd Zusammensetzungen und verfahren zur behandlung von amyloidosis mit sulphonatderivaten
US6609113B1 (en) * 1999-05-03 2003-08-19 The Chase Manhattan Bank Method and system for processing internet payments using the electronic funds transfer network
AUPQ014699A0 (en) * 1999-05-04 1999-05-27 Access Pharmaceuticals Australia Pty Limited Amplification of folate-mediated targeting to tumor cells using nanoparticles
US6562836B1 (en) 1999-05-24 2003-05-13 Queen's University Of Kingston Methods and compounds for inhibiting amyloid deposits
US6656730B1 (en) * 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
DE60033530T2 (de) 1999-08-24 2007-10-31 Medarex Inc. Humane antikörper gegen ctla-4 und deren verwendungen
JP2003507439A (ja) * 1999-08-26 2003-02-25 ブレンナー，シドニー 薬物コンジュゲートおよびその設計方法
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
CA2391534A1 (en) * 1999-11-15 2001-05-25 Drug Innovation & Design, Inc. Selective cellular targeting: multifunctional delivery vehicles
US8571975B1 (en) 1999-11-24 2013-10-29 Jpmorgan Chase Bank, N.A. System and method for sending money via E-mail over the internet
US6933108B2 (en) * 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
WO2001041784A1 (en) * 1999-12-09 2001-06-14 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
GB0002814D0 (en) 2000-02-09 2000-03-29 Univ York Nucleic acids and their uses
US8202979B2 (en) * 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US7491805B2 (en) * 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) * 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
EP1265995A2 (de) * 2000-02-11 2002-12-18 Ribozyme Pharmaceuticals, Inc. Verfahren und reagenzien zur modulation und diagnose der expression von den cd20 und nogo genen
US20030176385A1 (en) * 2000-02-15 2003-09-18 Jingfang Ju Antisense modulation of protein expression
NZ521898A (en) * 2000-03-31 2004-11-26 Purdue Research Foundation Use of a ligand-immunogen conjugate such as folate-FITC for enhancing an endogenous immune response
CN1095472C (zh) 2000-04-17 2002-12-04 上海复康医药科技发展有限公司 叶酸－多聚糖复合物，其制备方法和以该复合物为活性成分的药物组合物
JP5007409B2 (ja) 2000-05-08 2012-08-22 セルデックス リサーチ コーポレーション 樹状細胞に対するヒトモノクローナル抗体
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
DK1286704T3 (da) * 2000-06-02 2014-09-22 Univ Texas Ethylendicystein (EC)-glucose analoge konjugater
US20050209179A1 (en) * 2000-08-30 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
US20080032942A1 (en) * 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
WO2002036073A2 (en) * 2000-11-02 2002-05-10 Smithkline Beecham Corporation Receptor antagonist-lipid conjugates and delivery vehicles containing same
EP1341548A4 (de) * 2000-11-03 2006-06-14 Massachusetts Inst Technology VERFAHREN ZUR IDENTIFIZIERUNG VON BEHANDLUNGEN GEGEN NEUROTOXIZITÄT BEI ALZHEIMER-KRANKHEIT, DIE DURCH $g(b)-AMYLOIDPEPTIDE HERVORGERUFEN WIRD
US7067550B2 (en) * 2000-11-03 2006-06-27 Massachusetts Institute Of Technology Treatments for neurotoxicity in Alzheimer's Disease
AU2002217980A1 (en) 2000-12-01 2002-06-11 Cell Works Inc. Conjugates of glycosylated/galactosylated peptide
PT1372708E (pt) * 2001-02-13 2008-09-29 Us Gov Sec Army Vacina para imunização transcutânea
EP1389209B1 (de) * 2001-04-24 2009-04-08 Purdue Research Foundation Folat-mimetika und deren folatrezeptorbindende konjugate
EP1610751A4 (de) * 2001-04-26 2006-05-24 Univ Texas Therapeutisches mittel/ligand-konjugat-zusammensetzungen, ihre syntheseverfahren und ihre anwendung
KR20040015234A (ko) 2001-05-02 2004-02-18 펄듀 리서치 파운데이션 대식세포 매개된 질환의 치료와 진단
US20050176665A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050079610A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US20050287128A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TGF-beta and TGF-beta receptor gene expression using short interfering nucleic acid (siNA)
US20050164967A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US20050164966A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of type 1 insulin-like growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050124568A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of acetyl-CoA-carboxylase gene expression using short interfering nucleic acid (siNA)
US7109165B2 (en) * 2001-05-18 2006-09-19 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US20050119211A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
US20050196767A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acis (siNA)
US20050187174A1 (en) * 2001-05-18 2005-08-25 Sirna Therapeutics, Inc. RNA interference mediated inhibition of intercellular adhesion molecule (ICAM) gene expression using short interfering nucleic acid (siNA)
US20060241075A1 (en) * 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20060019913A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibtion of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US20050176664A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholinergic muscarinic receptor (CHRM3) gene expression using short interfering nucleic acid (siNA)
US20050267058A1 (en) * 2001-05-18 2005-12-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (sINA)
US7517864B2 (en) * 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050233996A1 (en) * 2002-02-20 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20050159382A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of polycomb group protein EZH2 gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) * 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US20060142226A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cholesteryl ester transfer protein (CETP) gene expression using short interfering nucleic acid (siNA)
US20040209831A1 (en) * 2002-02-20 2004-10-21 Mcswiggen James RNA interference mediated inhibition of hepatitis C virus (HCV) gene expression using short interfering nucleic acid (siNA)
US20050182009A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NF-Kappa B / REL-A gene expression using short interfering nucleic acid (siNA)
US20050164224A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US20050119212A1 (en) * 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA interference mediated inhibition of FAS and FASL gene expression using short interfering nucleic acid (siNA)
US20050054598A1 (en) * 2002-02-20 2005-03-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition hairless (HR) gene expression using short interfering nucleic acid (siNA)
US20040198682A1 (en) * 2001-11-30 2004-10-07 Mcswiggen James RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (siNA)
US20050153915A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of early growth response gene expression using short interfering nucleic acid (siNA)
US20050222066A1 (en) * 2001-05-18 2005-10-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20080161256A1 (en) * 2001-05-18 2008-07-03 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050164968A1 (en) * 2001-05-18 2005-07-28 Sirna Therapeutics, Inc. RNA interference mediated inhibition of ADAM33 gene expression using short interfering nucleic acid (siNA)
US20050136436A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of G72 and D-amino acid oxidase (DAAO) gene expression using short interfering nucleic acid (siNA)
US20050014172A1 (en) * 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20030130186A1 (en) * 2001-07-20 2003-07-10 Chandra Vargeese Conjugates and compositions for cellular delivery
US20050233344A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet derived growth factor (PDGF) and platelet derived growth factor receptor (PDGFR) gene expression using short interfering nucleic acid (siNA)
US20050176666A1 (en) * 2001-05-18 2005-08-11 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GPRA and AAA1 gene expression using short interfering nucleic acid (siNA)
US20080188430A1 (en) * 2001-05-18 2008-08-07 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US20060142225A1 (en) * 2001-05-18 2006-06-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of cyclin dependent kinase-2 (CDK2) gene expression using short interfering nucleic acid (siNA)
US20050130181A1 (en) * 2001-05-18 2005-06-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of wingless gene expression using short interfering nucleic acid (siNA)
US20050191638A1 (en) * 2002-02-20 2005-09-01 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20050159379A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc RNA interference mediated inhibition of gastric inhibitory polypeptide (GIP) and gastric inhibitory polypeptide receptor (GIPR) gene expression using short interfering nucleic acid (siNA)
US20050288242A1 (en) * 2001-05-18 2005-12-29 Sirna Therapeutics, Inc. RNA interference mediated inhibition of RAS gene expression using short interfering nucleic acid (siNA)
US20050182007A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050143333A1 (en) * 2001-05-18 2005-06-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (SINA)
US20050159380A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of angiopoietin gene expression using short interfering nucleic acid (siNA)
EP2415486B1 (de) 2001-05-18 2017-02-22 Sirna Therapeutics, Inc. Konjugate und Zusammensetzungen zur zellulären Verabreichung
US20050196765A1 (en) * 2001-05-18 2005-09-08 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint Kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US20050233997A1 (en) * 2001-05-18 2005-10-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US20050137155A1 (en) * 2001-05-18 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated treatment of Parkinson disease using short interfering nucleic acid (siNA)
US20050124567A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TRPM7 gene expression using short interfering nucleic acid (siNA)
US20050227935A1 (en) * 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US20070042983A1 (en) * 2001-05-18 2007-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050080031A1 (en) * 2001-05-18 2005-04-14 Sirna Therapeutics, Inc. Nucleic acid treatment of diseases or conditions related to levels of Ras, HER2 and HIV
US20050209180A1 (en) * 2001-05-18 2005-09-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20060211642A1 (en) * 2001-05-18 2006-09-21 Sirna Therapeutics, Inc. RNA inteference mediated inhibition of hepatitis C virus (HVC) gene expression using short interfering nucleic acid (siNA)
US20050153914A1 (en) * 2001-05-18 2005-07-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of MDR P-glycoprotein gene expression using short interfering nucleic acid (siNA)
US20050182006A1 (en) * 2001-05-18 2005-08-18 Sirna Therapeutics, Inc RNA interference mediated inhibition of protein kinase C alpha (PKC-alpha) gene expression using short interfering nucleic acid (siNA)
US20050159376A1 (en) * 2002-02-20 2005-07-21 Slrna Therapeutics, Inc. RNA interference mediated inhibition 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
US20050203040A1 (en) * 2001-05-18 2005-09-15 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
US20050124566A1 (en) * 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of myostatin gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20070270579A1 (en) * 2001-05-18 2007-11-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
US20050107595A1 (en) * 2001-06-20 2005-05-19 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
DK2000545T3 (da) 2001-06-20 2011-11-28 Genentech Inc Sammensætninger og fremgangsmåder til diagnose og behandling af lunge-tumor
US7803915B2 (en) * 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
AU2002315393A1 (en) 2001-06-21 2003-01-08 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
EP1409017A4 (de) * 2001-06-25 2006-05-24 Drug Innovation & Design Inc Zelltargeting, zusammensetzungen, verfahren und krebsbehandlungen auf basis exponentieller mustererkennung
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ573740A (en) 2001-09-18 2010-07-30 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor, particularly kidney tumor - TAT184
WO2003028634A2 (en) * 2001-09-28 2003-04-10 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
ATE516364T1 (de) 2001-10-09 2011-07-15 Isis Pharmaceuticals Inc Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
JP2005527639A (ja) 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
US7255874B1 (en) 2001-12-21 2007-08-14 Closure Medical Corporation Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
US7261875B2 (en) * 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
AU2002367318B2 (en) 2002-01-02 2007-07-12 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050222064A1 (en) * 2002-02-20 2005-10-06 Sirna Therapeutics, Inc. Polycationic compositions for cellular delivery of polynucleotides
US20050137153A1 (en) * 2002-02-20 2005-06-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of alpha-1 antitrypsin (AAT) gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20050096284A1 (en) * 2002-02-20 2005-05-05 Sirna Therapeutics, Inc. RNA interference mediated treatment of polyglutamine (polyQ) repeat expansion diseases using short interfering nucleic acid (siNA)
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
PT2264172T (pt) 2002-04-05 2017-12-06 Roche Innovation Ct Copenhagen As Compostos oligoméricos para a modulação da expressão do hif-1α.
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2003089593A2 (en) * 2002-04-19 2003-10-30 Endocyte, Inc. Adjuvant enhanced immunotherapy
US20030206916A1 (en) * 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
EP1549352A4 (de) 2002-05-06 2005-07-27 Nucleonics Inc Verfahren zur abgabe von nukleinsäuren
JP4814520B2 (ja) * 2002-05-15 2011-11-16 エンドサイト，インコーポレイテッド ビタミン−マイトマイシン結合体
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
WO2004009779A2 (en) 2002-07-19 2004-01-29 University Of South Carolina Compositions and methods for the modulation of gene expression in plants
CA2493364A1 (en) 2002-07-26 2004-02-12 Basf Plant Science Gmbh Inversion of the negative-selective effect of negative marker proteins using selection methods
EP1534340B1 (de) 2002-09-06 2011-11-16 Cerulean Pharma Inc. Polymere auf basis von cyclodextrin zur verabreichung von an diese kovalent gebundene arzneimittel
KR101360955B1 (ko) 2002-09-13 2014-02-10 레플리코르 인코포레이티드 비서열 상보적 항바이러스 올리고뉴클레오티드
US7229976B2 (en) 2002-09-26 2007-06-12 Isis Pharmaceuticals, Inc. Modulation of forkhead box O1A expression
ES2744275T3 (es) 2002-10-17 2020-02-24 Genmab As Anticuerpos monoclonales humanos contra CD20 para su uso en el tratamiento de esclerosis múltiple
EP1560597A4 (de) * 2002-10-29 2007-06-27 Pharmacia Corp Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
EP1560840B1 (de) 2002-11-05 2015-05-06 Isis Pharmaceuticals, Inc. Zusammensetzungen, die alternierende 2'-modifizierte nucleoside enthalten, zur verwendung in der genmodulation
EP1560839A4 (de) 2002-11-05 2008-04-23 Isis Pharmaceuticals Inc Chimäre oligomere verbindungen und derenverwendung in der genmodulation
JP2006515835A (ja) * 2002-11-07 2006-06-08 ボード　オブ　リージェンツ，　ザ　ユニバーシティ　オブ　テキサス　システム 組織特異的疾患のイメージングのための、エチレンジシステイン（ｅｃ）−薬物結合体、組成物、および方法
CA2505842A1 (en) * 2002-11-12 2004-07-15 Henri Tiedge Translational control by small, non-translatable rnas
JP4986109B2 (ja) 2002-11-13 2012-07-25 ジェンザイム・コーポレーション アポリポタンパク質ｂ発現のアンチセンス調節
DK2336318T3 (da) 2002-11-13 2013-07-15 Genzyme Corp Antisense-modulering af apolipoprotein b-ekspression
AU2002953073A0 (en) * 2002-11-21 2003-01-16 Access Pharmaceuticals Australia Pty Limited Amplification of biotin-mediated targeting
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
US20040231231A1 (en) * 2002-12-20 2004-11-25 Cataldo Dominic A. Use of colloidal clays for sustained release of active ingredients
EP2517729A3 (de) 2003-01-27 2013-01-02 Endocyte, Inc. Vitaminrezeptorbindende Wirkstofffreisetzungskonjugate
US7713738B2 (en) * 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
CA2515484C (en) 2003-02-11 2011-09-20 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
AU2004231740A1 (en) * 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
ES2368737T3 (es) 2003-04-23 2011-11-21 Medarex, Inc. Anticuerpos humanizados contra el receptor de interferon alfa 1 (ifnar-1).
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
EP1622572B1 (de) 2003-04-30 2017-12-20 Sirna Therapeutics, Inc. Konjugate und zusammensetzungen für die zelluläre abgabe
CA2524441C (en) * 2003-05-06 2012-03-20 Purdue Research Foundation Treatment of lupus targeting the macrophages or the folate receptor
EP1629281B1 (de) 2003-05-30 2008-10-29 Purdue Research Foundation Diagnoseverfahren für atherosklerose
IL156263A0 (en) * 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
CN1984921B (zh) 2003-06-03 2010-06-16 Isis药物公司 存活蛋白表达的调节
WO2004108088A2 (en) * 2003-06-04 2004-12-16 Canji, Inc. Methods and compositions for interferon therapy
US7754684B2 (en) * 2003-06-11 2010-07-13 Access Pharmaceuticals, Inc. Macromolecular platinum chelates
US20050142191A1 (en) 2003-06-23 2005-06-30 Neurochem (International) Limited Pharmaceutical formulations of amyloid inhibiting compounds
US20070010573A1 (en) * 2003-06-23 2007-01-11 Xianqi Kong Methods and compositions for treating amyloid-related diseases
US7244764B2 (en) * 2003-06-23 2007-07-17 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7414076B2 (en) * 2003-06-23 2008-08-19 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
US7812116B2 (en) * 2003-07-03 2010-10-12 Rush University Medical Center Immunogenic peptides
EP1502954A1 (de) 2003-07-31 2005-02-02 greenovation Biotech GmbH Gebrauch von Konstrukten mit rekombinanten Sequenzmotifen zur Erhöhung der Genexpression in Moosen
WO2005013901A2 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
NZ545134A (en) 2003-09-18 2009-06-26 Lilly Co Eli Modulation of eIF4E expression
NZ546272A (en) 2003-10-10 2009-05-31 Alchemia Oncology Pty Ltd The modulation of hyaluronan synthesis and degradation in the treatment of disease
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
CA2545679A1 (en) * 2003-11-12 2005-05-26 The University Of Georgia Research Foundation, Inc. Biotin-facilitated transport in gram negative bacteria
ES2472690T3 (es) 2003-11-17 2014-07-02 Genentech, Inc. Anticuerpo contra CD22 para el tratamiento de tumores de origen hematopoy�tico
US20050118124A1 (en) * 2003-12-01 2005-06-02 Reinhart Gale M. Compositions for treating keratinous surfaces
MXPA06005941A (es) 2003-12-10 2006-08-23 Medarex Inc Anticuerpos ip-10 y sus usos.
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
LT2418220T (lt) 2003-12-10 2017-10-10 E. R. Squibb & Sons, L.L.C. Interferono-alfa antikūnai ir jų panaudojimas
FR2864085B1 (fr) * 2003-12-18 2010-09-17 Centre Nat Rech Scient Nouveaux modulateurs du proteasome
AU2004303464B2 (en) 2003-12-23 2009-10-01 Santaris Pharma A/S Oligomeric compounds for the modulation of BCL-2
EP2363480A3 (de) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulierung der Glukokortikoid-Rezeptor-Expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
WO2005069994A2 (en) * 2004-01-22 2005-08-04 Immunomedics, Inc. Folate conjugates and complexes
EP1713900A4 (de) * 2004-01-27 2009-06-17 Compugen Ltd Verfahren und systeme zur kommentierung biomolekularer sequenzen
CA2556027C (en) * 2004-02-12 2015-11-24 Morphotek, Inc. Monoclonal antibodies that specifically block biological activity of a tumor antigen
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
EP1730309B1 (de) 2004-03-15 2016-05-04 Ionis Pharmaceuticals, Inc. Zusammensetzungen und verfahren zur optimierung der spaltung von rna durch rnase h
CA2560781C (en) 2004-03-22 2011-10-11 Kode Biotech Limited Synthetic membrane anchors
US10858384B2 (en) 2004-03-22 2020-12-08 Kode Biotech Limited Synthetic molecule constructs
AU2005231692B2 (en) * 2004-03-26 2011-01-27 Curis, Inc. RNA interference modulators of Hedgehog signaling and uses thereof
WO2006073419A2 (en) * 2004-04-01 2006-07-13 Gang Zheng Lipoprotein nanoplatforms
US20050244869A1 (en) * 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
US7674778B2 (en) * 2004-04-30 2010-03-09 Alnylam Pharmaceuticals Oligonucleotides comprising a conjugate group linked through a C5-modified pyrimidine
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US20060229267A1 (en) 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US20050272100A1 (en) * 2004-06-02 2005-12-08 Arthur Karlin Separation and quantification of biotinylated macromolecules
JP2008501694A (ja) * 2004-06-03 2008-01-24 アイシス ファーマシューティカルズ、インク． 遺伝子調節の使用のために個別に修飾された鎖を有する二本鎖組成物
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
CA2569036A1 (en) * 2004-06-03 2005-12-22 Balkrishen Bhat Chimeric gapped oligomeric compositions
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
EP2453024B1 (de) 2004-06-21 2017-12-06 The Board of Trustees of The Leland Stanford Junior University Differenziell exprimierte Gene und Leitungsbahnen bei bipolarer Störung und/oder schwerer depressiver Erkrankung
PT2662390T (pt) 2004-06-21 2017-10-09 Squibb & Sons Llc Anticorpos contra recetor 1 do interferão alfa e as suas utilizações
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
EP1799825B1 (de) 2004-10-05 2011-06-29 The California Institute of Technology Aptamer-regulierte nukleinsäuren und verwendungen davon
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
AU2005304110B2 (en) * 2004-11-09 2009-06-11 Enzon Pharmaceuticals, Inc. LNA oligonucleotides and the treatment of cancer
NZ555644A (en) * 2004-11-09 2009-04-30 Santaris Pharma As Potent LNA oligonucleotides for the inhibition of HIF-1A expression
US20060183800A1 (en) * 2004-11-12 2006-08-17 Xianqi Kong Methods and fluorinated compositions for treating amyloid-related diseases
CA2629751A1 (en) 2004-11-12 2006-05-18 The University Of British Columbia Antimicrobial peptides
US20060167057A1 (en) * 2004-11-16 2006-07-27 Xianqi Kong Compounds for the treatment of CNS and amyloid associated diseases
CA2592320C (en) * 2004-12-22 2015-11-24 Neurochem (International) Limited Methods and compositions for treating amyloid-related diseases
EP1827239B1 (de) * 2004-12-23 2019-04-17 Purdue Research Foundation Abbildungsverfahren für positronenemissions-tomographie
EP1855694B1 (de) 2005-02-09 2020-12-02 Sarepta Therapeutics, Inc. Antisense-zusammensetzung zur behandlung von muskelatrophie
KR20070110077A (ko) 2005-03-10 2007-11-15 제넨테크, 인크. 혈관 완전성을 조정하기 위한 방법 및 조성물
WO2006101845A2 (en) 2005-03-16 2006-09-28 Endocyte, Inc. Synthesis and purification of pteroic acid and conjugates thereof
SI2567976T1 (sl) 2005-03-23 2017-11-30 Genmab A/S Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma
ES2381201T3 (es) 2005-03-31 2012-05-24 Calando Pharmaceuticals, Inc. Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos
JP2009521206A (ja) 2005-04-22 2009-06-04 モルフォテック、インク． 免疫エフェクター活性を有する葉酸受容体アルファ陽性細胞に内部移行する抗体
SI2161336T1 (sl) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Humana monoklonska protitelesa za programirano smrt 1 (PD-1) in postopki za zdravljenje raka ob uporabi anti-PD-1 protiteles samih ali v kombinaciji z drugimi imunoterapevtiki
EP1899379B1 (de) 2005-06-20 2018-04-11 E. R. Squibb & Sons, L.L.C. Cd19-antikörper und anwendungen davon
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
US20070009434A1 (en) * 2005-07-05 2007-01-11 Low Philip S Imaging and therapeutic method using monocytes
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
JP2009504783A (ja) * 2005-08-19 2009-02-05 エンドサイト，インコーポレイテッド ビンカアルカロイド、類似体および誘導体のリガンド結合体
CN103893778A (zh) * 2005-08-19 2014-07-02 恩多塞特公司 多药物配体缀合物
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
EP1762575A1 (de) * 2005-09-12 2007-03-14 Ganymed Pharmaceuticals AG Identifizierung Tumor-assoziierter Antigene für Diagnoseund Therapie
WO2007031081A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S RNA ANTAGONIST COMPOUNDS FOR THE INHIBITION OF APO-Bl00 EXPRESSION
WO2007038346A2 (en) * 2005-09-23 2007-04-05 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
AU2006294663B2 (en) 2005-09-26 2012-03-22 Medarex, Inc. Human monoclonal antibodies to CD70
WO2007045477A2 (en) 2005-10-21 2007-04-26 Novartis Ag Human antibodies against il-13 and therapeutic uses
US20070099246A1 (en) * 2005-11-03 2007-05-03 Sandy John D Antibodies, assays and kits to quantitate cartilage destruction
US20090019557A1 (en) 2005-11-12 2009-01-15 Huda Akil Fgf2-related methods for diagnosing and treating depression
EP1966377A2 (de) 2005-11-21 2008-09-10 Isis Pharmaceuticals, Inc. Modulation der eif4e-bp2-expression
EP1790664A1 (de) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
SG174783A1 (en) 2005-12-08 2011-10-28 Medarex Inc Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 antibodies
IL173104A0 (en) 2006-01-12 2006-06-11 Yeda Res & Dev Siva and ubiquintination
WO2007084672A2 (en) 2006-01-17 2007-07-26 Medarex, Inc. Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues
US7951934B2 (en) 2006-01-26 2011-05-31 Isis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
WO2007092299A2 (en) * 2006-02-03 2007-08-16 Purdue Research Foundation Targeted conjugates and radiation
GB0603683D0 (en) 2006-02-23 2006-04-05 Novartis Ag Organic compounds
US20070232556A1 (en) * 2006-03-31 2007-10-04 Montine Thomas J Methods and compositions for the treatment of neurological diseases and disorders
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
US8758723B2 (en) 2006-04-19 2014-06-24 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
AU2007240732B2 (en) * 2006-04-21 2013-07-04 Amgen, Inc. Buffering agents for biopharmaceutical formulations
ES2387023T3 (es) 2006-04-21 2012-09-11 Amgen Inc. Dominios de región constante de inmunoglobulina con estabilidad mejorada
US20070258941A1 (en) * 2006-05-02 2007-11-08 Pfister Brian E Methods and compositions for remediation of disc herniation by modifying structure
CN101437943A (zh) * 2006-05-03 2009-05-20 波罗的科技发展有限公司 牢固结合的碱基-修饰的寡核苷酸和人工核酸酶组合的反义药剂
US20070259820A1 (en) * 2006-05-03 2007-11-08 The Regents Of The University Of Michigan Methods and reagents for activating heat shock protein 70
US20090209625A1 (en) * 2006-05-23 2009-08-20 Sanjay Bhanot Modulation of chrebp expression
WO2007139815A2 (en) * 2006-05-23 2007-12-06 Purdue Research Foundation Imaging and therapeutic method using progenitor cells
PE20080102A1 (es) * 2006-05-25 2008-02-11 Bristol Myers Squibb Co Conjugados de analogos de aziridinil-epotilona y composiciones farmaceuticas que comprenden los mismos
AR061181A1 (es) * 2006-05-25 2008-08-13 Bristol Myers Squibb Co Compuestos de aziridinil-epotilona
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
WO2008001370A2 (en) 2006-06-28 2008-01-03 Yeda Research And Development Co. Ltd Caspase-8 and inflammation, infection and wound healing
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
US20100316626A1 (en) * 2006-08-11 2010-12-16 The Government Of The United States Of America As Represented By The Secretary Methods for treatment and diagnosis of psychiatric disorders
MX2009002418A (es) 2006-09-05 2009-04-23 Medarex Inc Anticuerpos para las proteinas morfogenicas oseas y receptores de estas y metodos para su uso.
MX2009003306A (es) 2006-10-02 2009-04-23 Medarex Inc Anticuerpos humanos que se unen a cxcr4 y sus usos.
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CA2665567C (en) * 2006-10-06 2012-07-03 Amgen Inc. Stable formulations
CA2666246C (en) 2006-10-12 2013-12-31 Bellus Health (International) Limited Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
US7705132B2 (en) * 2006-10-20 2010-04-27 Amgen Inc. Stable polypeptide formulations
US8618248B2 (en) 2006-10-31 2013-12-31 President And Fellows Of Harvard College Phosphopeptide compositions and anti-phosphopeptide antibody compositions and methods of detecting phosphorylated peptides
US8685752B2 (en) * 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US8158595B2 (en) * 2006-11-09 2012-04-17 California Institute Of Technology Modular aptamer-regulated ribozymes
AU2007334264A1 (en) 2006-11-15 2008-06-26 Medarex, Inc. Human monoclonal antibodies to BTLA and methods of use
CN101626782B (zh) 2006-12-01 2013-03-27 梅达雷克斯公司 结合cd22的人抗体及其用途
CL2007003622A1 (es) 2006-12-13 2009-08-07 Medarex Inc Anticuerpo monoclonal humano anti-cd19; composicion que lo comprende; y metodo de inhibicion del crecimiento de celulas tumorales.
EP2097534A4 (de) 2006-12-14 2010-05-12 Medarex Inc Cd70-bindende antikörper und ihre verwendungen
EP2118118B1 (de) * 2007-01-19 2017-09-27 Exiqon A/S Vermittelte zelluläre verabreichung von lna-oligonukleotiden
JP2010516625A (ja) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド 制御された薬物送達のためのテザー基を有するポリマー−薬物コンジュゲート
US20100093836A1 (en) 2007-01-29 2010-04-15 Isis Pharmaceuticals, Inc Compounds and methods for modulating protein expression
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
EP2647388A1 (de) 2007-02-16 2013-10-09 Merrimack Pharmaceuticals, Inc. Antikörper gegen ERBB3 und Verwendungen davon
WO2008101231A2 (en) * 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
AU2008218199B2 (en) 2007-02-22 2013-10-31 Genentech, Inc. Methods for detecting inflammatory bowel disease
EP2139523B1 (de) * 2007-03-14 2014-10-22 Endocyte, Inc. Konjugate aus folat und tubulysinen zur zielgerichteten wirkstofffreisetzung
EP1970384A1 (de) 2007-03-14 2008-09-17 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
US8153863B2 (en) 2007-03-23 2012-04-10 New York University Transgenic plants expressing GLK1 and CCA1 having increased nitrogen assimilation capacity
AU2008230795B2 (en) 2007-03-27 2014-05-29 Bioassets, Llc Constructs and libraries comprising antibody surrogate light chain sequences
GB2463584B (en) * 2007-04-27 2012-02-01 Kode Biotech Ltd Carbohydrate-lipid constructs and their use in preventing or treating viral infection
GB0709835D0 (en) 2007-05-22 2007-07-04 Plant Bioscience Ltd Composition and method for modulating plant root hair development
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
WO2008147941A1 (en) 2007-05-25 2008-12-04 Bristol-Myers Squibb Company Processes for making epothilone compounds and analogs
WO2008148001A2 (en) * 2007-05-25 2008-12-04 Purdue Research Foundation Method of imaging localized infections
EP1997832A1 (de) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoklonale Antikörper gegen Claudin-18 zur Behandlung von Krebs
WO2009011855A2 (en) * 2007-07-16 2009-01-22 California Institute Of Technology Selection of nucleic acid-based sensor domains within nucleic acid switch platform
AU2008282218A1 (en) 2007-07-31 2009-02-05 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
EP3255144A1 (de) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering-konstrukt zur herstellung von transgenen mäusen, die menschlische immunoglobulin erzeugen können
US20120165387A1 (en) 2007-08-28 2012-06-28 Smolke Christina D General composition framework for ligand-controlled RNA regulatory systems
US8367815B2 (en) * 2007-08-28 2013-02-05 California Institute Of Technology Modular polynucleotides for ligand-controlled regulatory systems
US8394391B2 (en) * 2007-08-31 2013-03-12 University Of Utah Research Foundation Drug delivery vehicle that mimics viral properties
AU2008296361B2 (en) 2007-09-04 2013-04-11 Compugen, Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8865667B2 (en) * 2007-09-12 2014-10-21 California Institute Of Technology Higher-order cellular information processing devices
JP2010539978A (ja) 2007-10-02 2010-12-24 アムジェン インコーポレイテッド マイクロ−ｒｎａおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008316835B2 (en) 2007-10-25 2015-07-16 Endocyte, Inc. Tubulysins and processes for preparing
KR20100091170A (ko) 2007-11-02 2010-08-18 노파르티스 아게 저밀도-지단백질 수용체-관련 단백질 ６ (ｌｒｐ６)을 조정하기 위한 분자 및 방법
EP2217705A2 (de) * 2007-11-05 2010-08-18 Baltic Technology Development, Ltd. Verwendung von oligonukleotiden mit modifizierten basen bei der hybridisierung von nukleinsäuren
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
CA2705808A1 (en) * 2007-11-15 2009-05-22 Endocyte, Inc. Method of administering conjugates
KR20100100912A (ko) 2007-11-27 2010-09-15 더 유니버시티 오브 브리티쉬 콜롬비아 관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
CA2930393C (en) 2007-12-04 2022-11-29 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
CA2708171C (en) 2007-12-04 2018-02-27 Alnylam Pharmaceuticals, Inc. Folate conjugates
US9029524B2 (en) * 2007-12-10 2015-05-12 California Institute Of Technology Signal activated RNA interference
EP2244729B1 (de) 2008-01-18 2016-11-02 MedImmune, LLC Cystein-manipulierte antikörper zur stellenspezifischen konjugation
EP2240203B1 (de) 2008-02-05 2014-04-09 Bristol-Myers Squibb Company Alpha-5-beta-1-antikörper und ihre verwendungen
HUE028958T2 (en) 2008-02-08 2017-01-30 Medimmune Llc Anti-IFNAR1 antibodies with reduced Fc ligand affinity
US8470772B2 (en) 2008-02-27 2013-06-25 Temple University—Of the Commonwealth System of Higher Education Leptin agonist and methods of use
WO2009114085A2 (en) 2008-03-03 2009-09-17 The University Of Miami Allogeneic cancer cell-based immunotherapy
CN102036677A (zh) 2008-03-20 2011-04-27 迈阿密大学 热休克蛋白gp96的疫苗接种及其使用方法
WO2009123764A2 (en) 2008-04-04 2009-10-08 Calando Pharmaceuticals, Inc. Compositions and use of epas1 inhibitors
CA2721183C (en) 2008-04-11 2019-07-16 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
US10485879B2 (en) 2008-04-15 2019-11-26 Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Plasma cell cytokine vehicle containing fusion proteins for targeted introduction of siRNA into cells and tissues
US8703921B2 (en) 2008-04-15 2014-04-22 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Compositions and methods for delivering inhibitory oligonucleotides
EP3173424A1 (de) 2008-05-02 2017-05-31 Novartis Ag Verbesserte bindemoleküle auf fibronectin-basis und verwendungen davon
MX2010012931A (es) * 2008-05-30 2011-02-24 Dana Farber Cancer Inst Inc Metodos para tratar una enfermedad asociada con quinesina meiotica.
US8815818B2 (en) 2008-07-18 2014-08-26 Rxi Pharmaceuticals Corporation Phagocytic cell delivery of RNAI
WO2010017509A1 (en) * 2008-08-07 2010-02-11 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression for the treatment of cns related disorders
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
DK2331141T3 (en) 2008-08-25 2016-04-04 Excaliard Pharmaceuticals Inc Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
EP2166021A1 (de) 2008-09-16 2010-03-24 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
CA2736729A1 (en) 2008-09-29 2010-04-01 Ben Gurion University Of The Negev Research And Development Authority Amyloid beta-peptides and methods of use thereof
GB2465749B (en) 2008-11-25 2013-05-08 Algentech Sas Plant cell transformation method
GB2465748B (en) 2008-11-25 2012-04-25 Algentech Sas Plant cell transformation method
US8921329B2 (en) 2008-12-04 2014-12-30 Curna, Inc. Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO
US20110237649A1 (en) 2008-12-04 2011-09-29 Opko Curna, Llc Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CA2745492A1 (en) 2008-12-08 2010-06-17 Compugen Ltd. A polyclonal or monoclonal antibody or antibody binding fragment that binds to a tmem154 polypeptide
US9493774B2 (en) 2009-01-05 2016-11-15 Rxi Pharmaceuticals Corporation Inhibition of PCSK9 through RNAi
GB2467167B (en) 2009-01-26 2013-09-11 Algentech Sas Gene targeting in plants
WO2010090762A1 (en) 2009-02-04 2010-08-12 Rxi Pharmaceuticals Corporation Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
DK2396038T3 (en) 2009-02-12 2016-02-01 Curna Inc TREATMENT OF BRAIN-DERIVATED NEUROTROPHIC FACTOR- (BDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTION TO BDNF
KR101805199B1 (ko) 2009-02-12 2017-12-05 큐알엔에이, 인크. 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ)에 대한 자연 안티센스 전사체의 저해에 의한 신경교세포 유래된 신경영양성 인자 (ｇｄｎｆ) 관련된 질환의 치료
US8329882B2 (en) 2009-02-18 2012-12-11 California Institute Of Technology Genetic control of mammalian cells with synthetic RNA regulatory systems
WO2010102058A2 (en) 2009-03-04 2010-09-10 Curna, Inc. Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirt 1
ES2639026T3 (es) 2009-03-05 2017-10-25 Oxford Biotherapeutics Ltd. Anticuerpos totalmente humanos específicos para CADM1
EP2408919B1 (de) 2009-03-16 2017-10-18 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem nuklearfaktor (erythroid-derived)-like 2 (nrf2) mittels hemmung des natürlichen antisense-transkripts gegen nrf2
EP2408920B1 (de) 2009-03-17 2017-03-08 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem delta-like-1-homolog (dlk1) mittels hemmung des natürlichen antisense-transkripts gegen dlk1
ES2617434T3 (es) 2009-03-18 2017-06-19 Oncotherapy Science, Inc. Péptidos NEIL3 y vacunas que incluyen los mismos
US9145555B2 (en) 2009-04-02 2015-09-29 California Institute Of Technology Integrated—ligand-responsive microRNAs
UA108201C2 (xx) 2009-04-20 2015-04-10 Антитіла, специфічні для кадгерину-17
EP3524275A1 (de) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Angeborene immununterdrückung ermöglicht die wiederholte verabreichung von langen rna-molekülen
EA201101572A1 (ru) 2009-04-27 2012-05-30 Новартис Аг Композиции и способы применения терапевтических антител, специфичных в отношении субъединицы бета1 рецептора il-12
MA33279B1 (fr) 2009-04-27 2012-05-02 Novartis Ag Compositions et procédés pour l'augmentation de la croissance des muscles
ES2661787T3 (es) 2009-05-01 2018-04-04 Curna, Inc. Tratamiento de enfermedades relacionadas con hemoglobina (hbf/hbg) por inhibición de transcrito antisentido natural para hbf/hbg
KR20120088550A (ko) 2009-05-04 2012-08-08 애보트 리서치 비.브이. 증진된 생체내 안정성을 갖는 신경 성장 인자(ｎｇｆ)에 대한 항체
WO2010129746A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
WO2010129799A2 (en) 2009-05-06 2010-11-11 Curna, Inc. Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene
EP2430047B1 (de) 2009-05-13 2018-03-28 i2 Pharmaceuticals, Inc. Neutralisierende moleküle gegen influenza-viren
DK2432881T3 (en) 2009-05-18 2018-02-26 Curna Inc TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR
WO2011019423A2 (en) 2009-05-20 2011-02-17 Schering Corporation Modulation of pilr receptors to treat microbial infections
WO2010135695A2 (en) 2009-05-22 2010-11-25 Curna, Inc. TREATMENT OF TRANSCRIPTION FACTOR E3 (TFE3) and INSULIN RECEPTOR SUBSTRATE 2 (IRS2) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO TFE3
TWI507204B (zh) 2009-05-26 2015-11-11 Oncotherapy Science Inc Ｃｄｃ４５ｌ胜肽與含此胜肽之疫苗
US8791085B2 (en) 2009-05-28 2014-07-29 Curna, Inc. Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
EP2443241A1 (de) 2009-06-15 2012-04-25 Plant Bioscience Limited Herstellung von viralen kapsiden
EP2443237B1 (de) 2009-06-16 2017-02-22 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem kollagengen durch hemmung des natürlichen antisense-transkripts zu einem kollagengens
KR101702689B1 (ko) 2009-06-16 2017-02-06 큐알엔에이, 인크. Ｐｏｎ1에 대한 천연 안티센스 전사체의 억제에 의한 파라옥소나제 1(ｐｏｎ1) 관련된 질환의 치료
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
WO2010151671A2 (en) 2009-06-24 2010-12-29 Curna, Inc. Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
EP2446037B1 (de) 2009-06-26 2016-04-20 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem down-syndrom-gen durch hemmung des natürlichen antisense-transkripts zu einem down-syndrom-gen
US8394922B2 (en) 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
EP2462222B1 (de) 2009-08-05 2017-05-24 Chromocell Corporation Verbesserte pflanzen, mikroben und organismen
WO2011017516A2 (en) 2009-08-05 2011-02-10 Curna, Inc. Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
CA2771172C (en) 2009-08-25 2021-11-30 Opko Curna, Llc Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
US20110059111A1 (en) 2009-09-01 2011-03-10 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
EP3252068A3 (de) 2009-10-12 2018-03-14 Larry J. Smith Verfahren und zusammensetzungen zur modulation der genexpression unter verwendung in-vivo- oder in-vitro-verabreichten arzneistoffen auf oligonukleotidbasis
US20120231004A1 (en) 2009-10-13 2012-09-13 Oxford Biotherapeutic Ltd. Antibodies
MX2012004617A (es) 2009-10-22 2012-05-08 Genentech Inc Metodos y composiciones para modular activacion de hepsina de proteina que estimula macrofago.
EP2357239A1 (de) 2009-10-29 2011-08-17 Universität zu Köln Verfahren und Mittel für ein auswählbares Markierungssystem bei Pflanzen
WO2011051327A2 (en) 2009-10-30 2011-05-05 Novartis Ag Small antibody-like single chain proteins
WO2011051466A1 (en) 2009-11-02 2011-05-05 Novartis Ag Anti-idiotypic fibronectin-based binding molecules and uses thereof
WO2011056234A1 (en) 2009-11-06 2011-05-12 Fibrogen, Inc. Treatment for radiation-induced disorders
BR112012012210B8 (pt) * 2009-11-23 2021-05-25 Cerulean Pharma Inc conjugado de (cdp)-taxano de polímero contendo ciclodextrina, composição, composição farmacêutica, forma de dosagem, kit e uso de um conjugado de cdp-taxano
MX338694B (es) 2009-11-30 2016-04-27 Genentech Inc Composiciones y metodos para el diagnostico y el tratamiento de tumores.
WO2011067711A2 (en) 2009-12-01 2011-06-09 Compugen Ltd Novel heparanase splice variant
MX2012006580A (es) 2009-12-11 2012-09-28 Genecode As Metodo para facilitar la sobrevivencia de celulas neurales usando mimeticos de ligandos (gfl) de la familia gdnf o activadores de la ruta de señalizacion de ret.
TW201136604A (en) 2009-12-14 2011-11-01 Oncotherapy Science Inc TMEM22 peptides and vaccines including the same
JP6025567B2 (ja) 2009-12-16 2016-11-16 カッパーアールエヌエー，インコーポレイテッド 膜結合転写因子ペプチダーゼ、部位１（ｍｂｔｐｓ１）に対する天然アンチセンス転写物の阻害によるｍｂｔｐｓ１関連性疾患の治療
EP2513308B1 (de) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation von pilr zur behandlung immunerkrankungen
CN102686729B (zh) 2009-12-18 2015-09-23 箭头研究公司 用于治疗hsf1相关疾病的有机组合物
EP2516648B1 (de) 2009-12-23 2017-11-08 CuRNA, Inc. Behandlung von erkrankungen im zusammenhang mit dem häpatozyten-wachstumsfaktor (hgf) mittels hemmung des natürlichen antisense-transkripts gegen hgf
JP6031356B2 (ja) 2009-12-23 2016-11-24 カッパーアールエヌエー，インコーポレイテッド Ｕｃｐ２に対する天然アンチセンス転写産物の阻害による脱共役タンパク質２（ｕｃｐ２）関連疾患の治療
CA2785173A1 (en) 2009-12-29 2011-07-28 Curna, Inc. Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
KR101853508B1 (ko) 2009-12-29 2018-06-20 큐알엔에이, 인크. 종양 단백질 63 (ｐ63)에 대한 천연 안티센스 전사체의 억제에 의한 ｐ63에 관련된 질환의 치료
NO2521784T3 (de) 2010-01-04 2018-05-05
CN102822342B (zh) 2010-01-06 2017-05-10 库尔纳公司 通过抑制胰腺发育基因的天然反义转录物而治疗胰腺发育基因相关疾病
US9200277B2 (en) 2010-01-11 2015-12-01 Curna, Inc. Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
US8946182B2 (en) 2010-01-25 2015-02-03 Curna, Inc. Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
WO2011092233A1 (en) 2010-01-29 2011-08-04 Novartis Ag Yeast mating to produce high-affinity combinations of fibronectin-based binders
IN2012DN06588A (de) 2010-02-10 2015-10-23 Novartis Ag
EP2539452B1 (de) 2010-02-22 2016-07-27 CuRNA, Inc. Behandlung von durch pyrrolin-5-carboxylat-reduktase 1 (pycr1) vermittelten erkrankungen durch hemmung des natürlichen antisense-transkripts für pycr1
PE20130214A1 (es) 2010-02-23 2013-03-11 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
NZ724971A (en) 2010-02-24 2019-06-28 Immunogen Inc Folate receptor 1 antibodies and immunoconjugates and uses thereof
CA2792910A1 (en) 2010-03-11 2011-09-15 Yusuke Nakamura Hjurp peptides and vaccines including the same
AU2011227335B2 (en) 2010-03-17 2014-11-06 Abbott Research B.V. Anti-nerve growth factor (NGF) antibody compositions
EP2371864A1 (de) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoklonale Antikörper zur Krebsbehandlung
EP2550000A4 (de) 2010-03-24 2014-03-26 Advirna Inc Selbstfreisetzende rnai-verbindungen von reduzierter grösse
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
CA2794483C (en) 2010-03-26 2020-07-07 Trustees Of Dartmouth College Vista regulatory t cell mediator protein, vista binding agents and use thereof
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
TW201627003A (zh) 2010-04-02 2016-08-01 腫瘤療法 科學股份有限公司 Ｅｃｔ２胜肽及含此胜肽之疫苗
RU2610661C2 (ru) 2010-04-09 2017-02-14 Курна, Инк. Лечение заболеваний, связанных с фактором роста фибробластов 21 (fgf21), путем ингибирования природного антисмыслового транскрипта к fgf21
CA2796571C (en) 2010-04-13 2019-10-29 Celldex Therapeutics Inc. Antibodies that bind human cd27 and uses thereof
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
CN102985544A (zh) 2010-04-23 2013-03-20 诺瓦提斯公司 治疗β-ENaC-相关疾病的有机组合物
BR112012027547B1 (pt) 2010-04-29 2022-06-14 Ionis Pharmaceuticals, Inc Oligonucleotídeo modificado de fita simples, composição, e seus usos para tratar amiloidose transtirretina, reduzir os seus sintomas e para reduzir a expressão de mrna ou de proteína de transtirretina
EP2566893A1 (de) 2010-05-03 2013-03-13 F. Hoffmann-La Roche AG Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
JP2013525483A (ja) 2010-05-03 2013-06-20 カッパーアールエヌエー，インコーポレイテッド サーチュイン（ｓｉｒｔ）に対する天然アンチセンス転写物の阻害によるサーチュイン（ｓｉｒｔ）関連疾患の治療
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
US8957086B2 (en) 2010-05-05 2015-02-17 The Board Of Trustees Of The University Of Illinois Compounds and methods of treating brain disorders
AU2011249782B2 (en) 2010-05-06 2014-10-02 Novartis Ag Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
BR112012028306A2 (pt) 2010-05-06 2020-11-03 Novartis Ag anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações
DK2569430T3 (en) 2010-05-12 2019-02-04 Univ Columbia PROCEDURES FOR MANUFACTURING ENTEROENDOCRIN CELLS WHICH MANUFACTURE AND SECRET INSULIN
TWI531370B (zh) 2010-05-14 2016-05-01 可娜公司 藉由抑制ｐａｒ４天然反股轉錄本治療ｐａｒ４相關疾病
GB201008720D0 (en) 2010-05-25 2010-07-07 Univ Aberdeen RxLR-leader peptides and protein translocation
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
US20130209463A1 (en) 2010-06-30 2013-08-15 Compugen Ltd. Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
EP2593547B1 (de) 2010-07-14 2017-11-15 CuRNA, Inc. Behandlung von krankheiten im zusammenhang mit dem discs large homolog (dlg) durch hemmung des natürlichen antisense-transkripts an dlg
GB201012420D0 (en) 2010-07-23 2010-09-08 Univ Erasmus Medical Ct Foetal heamoglobin inhibitor
WO2012022734A2 (en) 2010-08-16 2012-02-23 Medimmune Limited Anti-icam-1 antibodies and methods of use
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
AU2011293437B2 (en) 2010-08-24 2015-09-17 Sgc Pharma, Inc. Salt compound
EP2616100B1 (de) 2010-09-17 2016-08-31 Compugen Ltd. Zusammensetzungen und verfahren zur behandlung von wirkstoffresistentem multiplem myelom
AU2011309689B2 (en) 2010-09-28 2015-01-15 Hadasit Medical Research Services & Development Ltd. Compositions and methods for treatment of hematological malignancies
WO2012045085A1 (en) 2010-10-01 2012-04-05 Oxford Biotherapeutics Ltd. Anti-rori antibodies
JP2013543384A (ja) 2010-10-05 2013-12-05 ノバルティス アーゲー 抗−ｉｌ１２ｒベータ１抗体ならびに自己免疫性および炎症性疾患の処置おけるその使用
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
CN103210086B (zh) 2010-10-06 2017-06-09 库尔纳公司 通过抑制唾液酸酶4(neu4)的天然反义转录物而治疗neu4相关疾病
CN103180445B (zh) 2010-10-22 2018-02-16 库尔纳公司 通过抑制α‑L‑艾杜糖醛酸酶(IDUA)的天然反义转录物而治疗IDUA相关疾病
CN103201387B (zh) 2010-10-27 2018-02-02 库尔纳公司 通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
EP2632472B1 (de) 2010-10-29 2017-12-13 Sirna Therapeutics, Inc. Durch rna-interferenz vermittelte inhibition einer genexpression unter verwendung von short-interfering-nukleinsäuren (sina)
US20140134181A1 (en) 2010-11-05 2014-05-15 Kenneth E. Lipson Treatment Method For Lung Remodeling Diseases
JP6071893B2 (ja) 2010-11-23 2017-02-01 カッパーアールエヌエー，インコーポレイテッド Ｎａｎｏｇへの天然アンチセンス転写物の阻害によるｎａｎｏｇ関連疾患の治療
EP2643353A1 (de) 2010-11-24 2013-10-02 Novartis AG Multispezifische moleküle
TWI593416B (zh) 2011-02-02 2017-08-01 艾克厘德製藥公司 利用針對結締組織生長因子（ｃｔｇｆ）目標之反義化合物治療瘢痕或肥厚性疤痕之方法
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
KR20230013283A (ko) 2011-04-01 2023-01-26 이뮤노젠 아이엔씨 Folr1 암 치료의 효능을 증가시키기 위한 방법
US8658783B2 (en) 2011-04-13 2014-02-25 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
JP2014517685A (ja) 2011-04-15 2014-07-24 コンピュゲン エルティーディー． 免疫関連疾患およびがんの治療のためのポリペプチドおよびポリヌクレオチドならびにそれらの使用
CN103620036B (zh) 2011-06-09 2016-12-21 库尔纳公司 通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
CA2839437A1 (en) 2011-06-16 2012-12-20 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 4 expression
GEP201706667B (en) 2011-06-28 2017-05-25 Berlin - Chemie Ag Antibodies to adp-ribosyl cyclase 2
EP2726503B1 (de) 2011-06-30 2019-09-04 Compugen Ltd. Polypetide und ihre verwendung zur behandlung von autoimmunerkrankungen und infektionen
KR20140058532A (ko) 2011-06-30 2014-05-14 겐자임 코포레이션 Ｔ-세포 활성화 억제제
US9365651B2 (en) 2011-07-01 2016-06-14 Novartis Ag Method for treating metabolic disorders by administration of an anti-ActRIIB antibody
US9238689B2 (en) 2011-07-15 2016-01-19 Morpho Sys AG Antibodies that are cross-reactive for macrophage migration inhibitory factor (MIF) and D-dopachrome tautomerase (D-DT)
US9549981B2 (en) 2011-07-19 2017-01-24 Philogen S.P.A. Sequential antibody therapy
CA2842860A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies, Llc Sur-binding proteins
CA2847283C (en) 2011-09-02 2023-03-14 Novartis Ag Organic compositions to treat hsf1-related diseases
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
WO2013043569A1 (en) 2011-09-20 2013-03-28 Vical Incorporated Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
KR101840512B1 (ko) 2011-09-20 2018-03-20 아이오니스 파마수티컬즈, 인코포레이티드 Gcgr 발현의 안티센스 조절
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
KR20140084232A (ko) 2011-10-25 2014-07-04 아이시스 파마수티컬즈 인코포레이티드 Gccr 발현의 안티센스 조절
BR112014009176B1 (pt) 2011-10-28 2022-08-30 Oncotherapy Science, Inc Composição para indução de linfócito t citotóxico (ctl), uso no tratamento e profilaxia de câncer e indução de resposta imune contra câncer e métodos in vitro para indução de ctl
AU2012349736A1 (en) 2011-12-05 2014-06-26 Novartis Ag Antibodies for epidermal growth factor receptor 3 (HER3) directed to domain II of HER3
BR112014013412A8 (pt) 2011-12-05 2021-06-08 Novartis Ag anticorpos para o receptor 3 do fator de crescimento epidérmico (her3), e seus usos
EP2789348B1 (de) 2011-12-07 2021-08-04 Universidade do Minho Liposomen und entsprechendes herstellungsverfahren
EP3446707A1 (de) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogatbindungsproteine
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
WO2013105022A2 (en) 2012-01-09 2013-07-18 Novartis Ag Organic compositions to treat beta-catenin-related diseases
CA2848985A1 (en) 2012-02-01 2013-08-08 Compugen Ltd. C10rf32 antibodies, and uses thereof for treatment of cancer
HUE033704T2 (en) 2012-02-13 2017-12-28 Bristol Myers Squibb Co Enediyne Compounds, its conjugates and uses, and methods for doing so
TR201815503T4 (tr) 2012-03-15 2018-11-21 Curna Inc Beyin kaynaklı nörotrofik faktör (bknf) ile ilişkili hastalıkların doğal antisens transkriptinin bknf'ye inhibisyonu ile muamelesi.
ES2644778T3 (es) 2012-03-16 2017-11-30 Merck Patent Gmbh Administración dirigida de lípidos-aminoácidos
MX359736B (es) 2012-03-16 2018-10-09 Merck Patent Gmbh Lipidos de aminoacidos.
US20150079100A1 (en) 2012-03-23 2015-03-19 Bristol-Myers Squibb Company Methods of treatments using ctla-4 antibodies
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
WO2013158273A1 (en) 2012-04-20 2013-10-24 Abbvie Inc. Methods to modulate c-terminal lysine variant distribution
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
AU2013263349B2 (en) 2012-05-17 2016-09-08 Extend Biosciences, Inc Carriers for improved drug delivery
WO2013176754A1 (en) 2012-05-24 2013-11-28 Abbvie Inc. Novel purification of antibodies using hydrophobic interaction chromatography
JP6321633B2 (ja) 2012-06-04 2018-05-09 ノバルティス アーゲー 部位特異的標識法およびそれによって生成される分子
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
WO2014039983A1 (en) 2012-09-07 2014-03-13 The Trustees Of Dartmouth College Vista modulators for diagnosis and treatment of cancer
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
PL2890717T3 (pl) 2012-08-31 2020-08-10 Immunogen, Inc. Testy i zestawy diagnostyczne do wykrywania receptora folianu
EP2943194A1 (de) 2012-09-17 2015-11-18 Chemedest Ltd. Behandlung peripherer neuropathie mit gfr (alpha)-typ-3 -rezeptoragonisten
WO2014055493A1 (en) 2012-10-02 2014-04-10 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
MX2015004757A (es) 2012-10-16 2015-07-17 Endocyte Inc Conjugados de suministro de farmacos que contienen aminoacidos no naturales y metodo para usarlos.
CN103772503B (zh) 2012-10-22 2017-05-10 泉盛生物科技股份有限公司 介白素‑6抗体及其用途
EP2914742A1 (de) 2012-11-05 2015-09-09 Pronai Therapeutics, Inc. Verfahren zur verwendung von biomarkern zur behandlung von krebs durch modulation der bcl2-expression
MX2015005874A (es) 2012-11-09 2015-09-10 Pfizer Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
SI2935320T1 (sl) 2012-12-18 2019-12-31 Novartis Ag Stabilizirani polipeptidi inzulinu podobnega rastnega faktorja
CN115925957A (zh) 2013-02-08 2023-04-07 Irm责任有限公司 用于修饰抗体以制备免疫缀合物的特定位点
PL2953969T3 (pl) 2013-02-08 2020-02-28 Novartis Ag Przeciwciała anty-il-17a i ich zastosowanie w leczeniu zaburzeń autoimmunologicznych i zapalnych
WO2014124258A2 (en) 2013-02-08 2014-08-14 Irm Llc Specific sites for modifying antibodies to make immunoconjugates
PT2956173T (pt) 2013-02-14 2017-06-26 Bristol Myers Squibb Co Compostos de tubulisina, métodos de produção e utilização
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
CA2926301A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. Low acidic species compositions and methods for producing and using the same
EP2970375A1 (de) 2013-03-14 2016-01-20 AbbVie Inc. Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
WO2014159239A2 (en) 2013-03-14 2014-10-02 Novartis Ag Antibodies against notch 3
US10052364B2 (en) 2013-03-15 2018-08-21 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
ES2701051T3 (es) 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
DK3007704T3 (da) 2013-06-13 2021-03-29 Antisense Therapeutics Ltd Kombinationsterapi til akromegali
US9718811B2 (en) 2013-06-26 2017-08-01 Helmholtz Zentrum München—Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) (S)-enantiomer of mepazine
EP3470420A1 (de) 2013-08-14 2019-04-17 Institute Of Genetics And Developmental Biology Verfahren zur modulation der samen- und organgrösse bei pflanzen
AU2014312086B2 (en) 2013-08-30 2020-03-12 Immunogen, Inc. Antibodies and assays for detection of folate receptor 1
EP3041935A1 (de) 2013-09-05 2016-07-13 Sage Therapeutics, Inc. Antisense-induzierter exon2-einschluss in saurer alpha-glucosidase
US20160223547A1 (en) 2013-09-13 2016-08-04 Angels SIERRA JIMÉNLEZ Marker for predicting metastasis of breast cancer
EP3047023B1 (de) 2013-09-19 2019-09-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Zusammensetzungen und methoden zur inhibierung des jc virus (jcv)
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
EP3052123A1 (de) 2013-10-02 2016-08-10 Novartis Ag Insulinähnliche wachstumsfaktor-mimetika zur verwendung in einer therapie
EP3055331B1 (de) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Konjugierte antikörper gegen ly75 zur behandlung von krebs
GB201319876D0 (en) 2013-11-11 2013-12-25 Plant Bioscience Ltd Methods of modulating seed and organ size in plants
IL245001B2 (en) 2013-11-13 2023-05-01 Pfizer Antibodies specific to cancer necrosis factor-like ligand 1a and preparations and their uses
US11162937B2 (en) 2013-11-19 2021-11-02 Purdue Research Foundation Patient selection method for inflammation
UY35874A (es) 2013-12-12 2015-07-31 Novartis Ag Un proceso para la preparación de una composición de proteínas pegiladas
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
JP6590810B2 (ja) 2013-12-24 2019-10-16 ヤンセン ファーマシューティカ エヌブイ 抗ｖｉｓｔａ抗体および断片
WO2015109212A1 (en) 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
JP6736467B2 (ja) 2014-02-04 2020-08-05 ジェネンテック， インコーポレイテッド 平滑化変異体及びその使用方法
JP2017509337A (ja) 2014-03-12 2017-04-06 ノバルティス アーゲー イムノコンジュゲートを作製する抗体を修飾するための特定部位
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
GB201408623D0 (en) 2014-05-15 2014-07-02 Santaris Pharma As Oligomers and oligomer conjugates
HUE047385T2 (hu) 2014-06-06 2020-04-28 Bristol Myers Squibb Co Antitestek glükokortikoid indukált tumornekrózis faktor receptor (GITR) ellen és annak felhasználásai
WO2015191881A2 (en) 2014-06-11 2015-12-17 Green Kathy A Use of vista agonists and antagonists to suppress or enhance humoral immunity
US20170291939A1 (en) 2014-06-25 2017-10-12 Novartis Ag Antibodies specific for il-17a fused to hyaluronan binding peptide tags
CA2985344A1 (en) 2014-06-26 2015-12-30 The Trustees Of Columbia University In The City Of New York Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
US20170226552A1 (en) 2014-07-03 2017-08-10 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
WO2016007764A1 (en) 2014-07-09 2016-01-14 Abbvie Inc. Methods for modulating the glycosylation profile of recombinant proteins using non-commonly used sugars
US20170291956A1 (en) 2014-07-16 2017-10-12 David Livingston HER3 Inhibition in Low-grade Serous Ovarian Cancers
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
WO2016025331A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
EP3185885B1 (de) 2014-08-26 2020-08-19 Compugen Ltd. Polypeptide und verwendungen davon als arzneimittel zur behandlung von autoimmunerkrankungen
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
EP2993174A1 (de) 2014-09-08 2016-03-09 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Pyrazolopyridinderivate und deren Verwendung in der Therapie
US9732119B2 (en) 2014-10-10 2017-08-15 Bristol-Myers Squibb Company Immunomodulators
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
EP3217982A1 (de) 2014-11-10 2017-09-20 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Spiropyrazinderivate als inhibitoren von nichtapoptotischem reguliertem zelltod
JOP20200092A1 (ar) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
US9856292B2 (en) 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
WO2016075670A1 (en) 2014-11-14 2016-05-19 Novartis Ag Antibody drug conjugates
EP3226889A4 (de) 2014-11-19 2018-11-21 The Trustees of Columbia University in the City of New York Osteocalcin zur behandlung von gebrechlichkeit im zusammenhang mit alterung
DK3221346T3 (da) 2014-11-21 2020-10-12 Bristol Myers Squibb Co Antistoffer omfattende modificerede konstante områder af tungkæden
TWI758928B (zh) 2014-11-21 2022-03-21 美商必治妥美雅史谷比公司 抗cd73抗體及其用途
JP6701217B2 (ja) 2014-11-25 2020-05-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 生物学的製剤の１８ｆ−放射性標識方法および組成物
CN114591420A (zh) 2014-11-25 2022-06-07 百时美施贵宝公司 用于成像的新型pd-l1结合多肽
WO2016087514A1 (en) 2014-12-02 2016-06-09 Cemm - Forschungszentrum Für Molekulare Medizin Gmbh Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
CA2969730A1 (en) 2014-12-05 2016-06-09 Immunext, Inc. Identification of vsig8 as the putative vista receptor and its use thereof to produce vista/vsig8 modulators
CN108367003B (zh) 2014-12-12 2022-01-21 麻省总医院 乳腺癌脑转移的治疗
US9861680B2 (en) 2014-12-18 2018-01-09 Bristol-Myers Squibb Company Immunomodulators
CN113563468A (zh) 2014-12-19 2021-10-29 雷根尼桑斯公司 结合人c6的抗体及其用途
US9944678B2 (en) 2014-12-19 2018-04-17 Bristol-Myers Squibb Company Immunomodulators
JP6180663B2 (ja) 2014-12-23 2017-08-16 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｔｉｇｉｔに対する抗体
WO2016115201A1 (en) 2015-01-14 2016-07-21 Bristol-Myers Squibb Company Heteroarylene-bridged benzodiazepine dimers, conjugates thereof, and methods of making and using
WO2016120828A1 (en) 2015-01-30 2016-08-04 Novartis Ag Treatment of breast cancer by m-csf antagonist
US20160222060A1 (en) 2015-02-04 2016-08-04 Bristol-Myers Squibb Company Immunomodulators
WO2016144773A1 (en) 2015-03-06 2016-09-15 Abbvie Inc. Arabinosylated glycoproteins
US20180044429A1 (en) 2015-03-09 2018-02-15 Celldex Therapeutics, Inc. Cd27 agonists
US9809625B2 (en) 2015-03-18 2017-11-07 Bristol-Myers Squibb Company Immunomodulators
MA41795A (fr) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc Exclusion d'un exon induite par des composés antisens dans la myostatine
JP2018510913A (ja) 2015-04-10 2018-04-19 ヘルムホルツ・ツェントルム・ミュンヘン・ドイチェス・フォーシュンクスツェントルム・フュア・ゲズントハイト・ウント・ウンベルト・ゲーエムベーハー 抗ウイルス剤としての使用のためのピロン誘導体
JP7245649B2 (ja) 2015-05-01 2023-03-24 アリスタ ファーマスーティカルス インク． 眼疾患を治療するためのアディポネクチンペプチド模倣薬（関連出願の相互参照）
WO2016187068A1 (en) 2015-05-15 2016-11-24 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
US10568852B2 (en) 2015-05-22 2020-02-25 Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) Combination compositions and their use in methods for treating obesity and obesity-related disorders
WO2016191556A1 (en) * 2015-05-26 2016-12-01 The General Hospital Corporation Liposomal nanoconstructs and methods of making and using the same
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
EP3851531A1 (de) 2015-06-01 2021-07-21 Sarepta Therapeutics, Inc. Antisense-induzierte exonexklusion in typ-vii-kollagen
EP3310813A1 (de) 2015-06-17 2018-04-25 Novartis AG Antikörper-wirkstoff-konjugate
BR112017027870A2 (pt) 2015-06-24 2018-08-28 Janssen Pharmaceutica Nv anticorpos e fragmentos anti-vista
WO2017004016A1 (en) 2015-06-29 2017-01-05 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
EP3971211A1 (de) 2015-07-13 2022-03-23 Compugen Ltd. Hide1-zusammensetzungen und verfahren
CA3025896A1 (en) 2015-07-23 2017-01-26 The Regents Of The University Of California Antibodies to coagulation factor xia and uses thereof
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
US10954300B2 (en) 2015-09-28 2021-03-23 The Trustees Of Columbia University In The City Of New York Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
RU2638457C2 (ru) 2015-09-28 2017-12-13 Общество С Ограниченной Ответственностью "Онкомакс" Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3355914B1 (de) 2015-09-29 2024-03-06 The General Hospital Corporation Eine bcg-haltige zusammensetzung zur cholesterolsenkung.
EP3359668A4 (de) 2015-10-09 2019-06-05 Sarepta Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von duchenne-muskeldystrophie und damit assoziierten erkrankungen
EP3365369A1 (de) 2015-10-23 2018-08-29 Pfizer Inc Anti-il-2-antikörper sowie zusammensetzungen und verwendungen davon
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
CA3007424A1 (en) 2015-11-05 2017-05-11 Children's Hospital Los Angeles "mobilizing leukemia cells"
CN106699889A (zh) 2015-11-18 2017-05-24 礼进生物医药科技（上海）有限公司 抗pd-1抗体及其治疗用途
WO2017087678A2 (en) 2015-11-19 2017-05-26 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof
KR102630475B1 (ko) 2015-11-30 2024-01-26 브리스톨-마이어스 스큅 컴퍼니 항 인간 ip-10 항체 및 이의 용도
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017125897A1 (en) 2016-01-21 2017-07-27 Novartis Ag Multispecific molecules targeting cll-1
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
WO2017137830A1 (en) 2016-02-12 2017-08-17 Janssen Pharmaceutica Nv Anti-vista (b7h5) antibodies
JP2019511911A (ja) 2016-02-17 2019-05-09 ノバルティス アーゲー Ｔｇｆベータ２抗体
AU2016394956B2 (en) 2016-03-04 2024-02-08 The Rockefeller University Antibodies to CD40 with enhanced agonist activity
SG10201913033UA (en) 2016-03-04 2020-03-30 Bristol Myers Squibb Co Combination therapy with anti-cd73 antibodies
US10143746B2 (en) 2016-03-04 2018-12-04 Bristol-Myers Squibb Company Immunomodulators
US10358463B2 (en) 2016-04-05 2019-07-23 Bristol-Myers Squibb Company Immunomodulators
UA125382C2 (uk) 2016-04-15 2022-03-02 Імьюнекст Інк. Антитіла проти людського vista та їх застосування
WO2017184619A2 (en) 2016-04-18 2017-10-26 Celldex Therapeutics, Inc. Agonistic antibodies that bind human cd40 and uses thereof
WO2017184529A1 (en) 2016-04-18 2017-10-26 Sarepta Therapeutics, Inc. Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene
EP3445850B1 (de) 2016-04-22 2021-10-27 BioNTech SE Verfahren zur bereitstellung von einzelsträngiger rna
AU2017268291B2 (en) 2016-05-19 2022-09-29 Bristol-Myers Squibb Company PET-imaging immunomodulators
JP7016323B2 (ja) 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
EP3260542A1 (de) 2016-06-20 2017-12-27 Algentech Proteinproduktion in pflanzenzellen
PE20190418A1 (es) 2016-07-14 2019-03-19 Bristol Myers Squibb Co Anticuerpos contra proteina 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos
WO2018035391A1 (en) 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
EP3305781A1 (de) 2016-10-07 2018-04-11 Deutsches Krebsforschungszentrum Chemische substanzen welche die enzymatische aktivität der humanen kallikrein-related peptidase 6 (klk6) hemmen.
CU20190036A7 (es) 2016-10-13 2019-11-04 Massachusetts Inst Technology Anticuerpos que se unen a la proteína de envoltura del virus zika
KR102526034B1 (ko) 2016-11-07 2023-04-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
US10538556B2 (en) 2016-11-07 2020-01-21 Colorado State University Research Foundation Anti-HIV peptides
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
WO2018127919A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A SIRP1 alpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
CN110312736B (zh) 2017-01-23 2023-05-09 苏州康宁杰瑞生物科技有限公司 Pd-l1结合多肽或化合物
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル－マイヤーズ スクイブ カンパニー アルファ－シヌクレインに対する抗体およびその使用
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
US11324820B2 (en) 2017-04-18 2022-05-10 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (HBV) infection
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10994025B2 (en) 2017-05-12 2021-05-04 Massachusetts Institute Of Technology Argonaute protein-double stranded RNA complexes and uses related thereto
EP3625251A1 (de) 2017-05-15 2020-03-25 University Of Rochester Breit neutralisierende monoklonale anti-influenza-antikörper und verwendungen davon
MX2019013132A (es) 2017-05-25 2020-01-27 Bristol Myers Squibb Co Anticuerpos que comprenden regiones constantes pesadas modificadas.
CN110997693A (zh) 2017-06-07 2020-04-10 阿德克斯公司 τ聚集抑制剂
WO2018237153A1 (en) 2017-06-23 2018-12-27 Bristol-Myers Squibb Company IMMUNOMODULATORS ACTING AS PD-1 ANTAGONISTS
WO2018233333A1 (zh) 2017-06-23 2018-12-27 苏州博聚华生物医药科技有限公司 一种靶向人肿瘤干细胞的单克隆抗体及其应用
EP3668886A2 (de) 2017-08-18 2020-06-24 Adrx, Inc. Peptidinhibitoren der tau-aggregation
KR20200095455A (ko) 2017-08-28 2020-08-10 상하이 일레 바이오테크놀로지 씨오., 엘티디. 폴리펩티드 및 폴리펩티드에 결합되는 항체
EP3692053A1 (de) 2017-10-03 2020-08-12 Bristol-Myers Squibb Company Immunmodulatoren
WO2019075090A1 (en) 2017-10-10 2019-04-18 Tilos Therapeutics, Inc. ANTI-LAP ANTIBODIES AND USES THEREOF
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. ANTISENSE OLIGOMERIC COMPOUNDS
US10973878B2 (en) 2017-10-26 2021-04-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd. Recombinant fusion protein containing an anti-PD-L1 antibody
CN111542544A (zh) 2017-11-01 2020-08-14 百时美施贵宝公司 用于治疗癌症的免疫刺激性激动性抗体
CA3079313A1 (en) 2017-11-02 2019-05-09 Oxford Biotherapeutics Ltd Antibodies and methods of use
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
CN111615520A (zh) 2017-12-01 2020-09-01 辉瑞大药厂 抗cxcr5抗体及其组合物和用途
EP4295915A3 (de) 2017-12-20 2024-05-22 Harbour Biomed (Shanghai) Co., Ltd Ctla-4-bindende antikörper und verwendungen davon
SG11202004966PA (en) 2017-12-21 2020-06-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising a dementia
SG11202004971YA (en) 2017-12-21 2020-06-29 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising motor neuron diseases
JP7284759B2 (ja) 2017-12-27 2023-05-31 ブリストル－マイヤーズ スクイブ カンパニー 抗ｃｄ４０抗体およびその使用
EP3737700A1 (de) 2018-01-12 2020-11-18 Bristol-Myers Squibb Company Antikörper gegen tim3 und verwendungen davon
CA3093509A1 (en) 2018-03-15 2019-09-19 Biontech Rna Pharmaceuticals Gmbh 5'-cap-tri nucleotide- or higher oligonucleotide compounds and their uses in stabilizing rna, expressing proteins and in therapy
CN111886256A (zh) 2018-03-23 2020-11-03 百时美施贵宝公司 抗mica和/或micb抗体及其用途
EP3777889A4 (de) 2018-03-26 2022-01-26 Shanghai Yile Biotechnology Co., Ltd. Verwendung von probdnf-regulator in b-zell-verwandten krankheiten
WO2019185129A1 (en) 2018-03-27 2019-10-03 The University Court Of The University Of Glasgow Bacterial pathogen derived resistance in plants
CA3094756A1 (en) 2018-03-29 2019-10-03 Pfizer Inc. Lfa3 variants and compositions and uses thereof
JP2021519594A (ja) 2018-04-02 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｔｒｅｍ−１抗体およびその使用
AU2019247490A1 (en) 2018-04-06 2020-10-22 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
MX2020010604A (es) 2018-04-12 2020-10-20 Bristol Myers Squibb Co Terapia de combinacion anticancer con anticuerpo antagonista del grupo de diferenciacion 73 (cd73) y anticuerpo antagonista del eje proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1).
US11459393B2 (en) 2018-04-17 2022-10-04 Celldex Therapeutics, Inc. Anti-CD27 and anti-PD-L1 antibodies and bispecific constructs
US20210179602A1 (en) 2018-04-20 2021-06-17 Iomx Therapeutics Ag A 5-thiazolecarboxamide kinase inhibitor and uses thereof
WO2019213384A1 (en) 2018-05-03 2019-11-07 University Of Rochester Anti-influenza neuraminidase monoclonal antibodies and uses thereof
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
KR20210016390A (ko) 2018-06-01 2021-02-15 노파르티스 아게 Bcma에 대한 결합 분자 및 이의 용도
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
WO2020014298A1 (en) 2018-07-10 2020-01-16 Rush University Medical Center Use of immunomodulators to control infection and stimulate healing in normal and diabetic wounds
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
WO2020029982A1 (en) 2018-08-08 2020-02-13 Immuneonco Biopharmaceuticals (Shanghai) Co., Ltd Recombinant bifunctional protein targeting cd47 and her2
TW202023574A (zh) 2018-08-13 2020-07-01 美商阿尼拉製藥公司 Ｂ型肝炎病毒（ＨＢＶ）ｄｓＲＮＡ劑組合物及其使用方法
AU2019336197A1 (en) 2018-09-07 2021-02-18 Pfizer Inc. Anti-avb8 antibodies and compositions and uses thereof
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
CN113164780A (zh) 2018-10-10 2021-07-23 泰洛斯治疗公司 抗lap抗体变体及其用途
WO2020084005A1 (en) 2018-10-23 2020-04-30 Myelopro Diagnostics And Research Gmbh Compounds targeting mutant calreticulin
EP3643713A1 (de) 2018-10-23 2020-04-29 iOmx Therapeutics AG Heterocyclische kinasehemmer und verwendungen davon
EP3876989A4 (de) 2018-11-09 2022-12-07 University of Massachusetts Anti-cfae-antikörper und verfahren zur verwendung
KR20210092769A (ko) 2018-11-16 2021-07-26 브리스톨-마이어스 스큅 컴퍼니 항-nkg2a 항체 및 그의 용도
EP3887397A1 (de) 2018-11-28 2021-10-06 Bristol-Myers Squibb Company Antikörper mit modifizierten schweren konstanten regionen
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
CN116063513A (zh) 2018-12-21 2023-05-05 Ose免疫疗法公司 人源化的抗人pd-1抗体
CN113195541A (zh) 2018-12-21 2021-07-30 诺华股份有限公司 针对pmel17的抗体及其缀合物
US20230071889A1 (en) 2018-12-21 2023-03-09 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
BR112021012027A2 (pt) 2018-12-21 2021-11-03 Ose Immunotherapeutics Molécula bifuncional direcionada contra pd-1 humano
AU2019409805A1 (en) 2018-12-21 2021-07-22 Ose Immunotherapeutics Bifunctional anti-PD-1/SIRPA molecule
WO2020132378A2 (en) 2018-12-22 2020-06-25 Gliapharm Sa Compositions and methods of treatment for neurological disorders comprising depression
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
US20230158167A1 (en) 2019-03-08 2023-05-25 AbTis Co., Ltd. Site-specific antibody conjugation and antibody-drug conjugate as specific embodiment thereof
EP3947458A1 (de) 2019-04-03 2022-02-09 Genzyme Corporation Anti-alpha-beta-tcr bindende polypeptide mit reduzierter fragmentierung
KR20220010527A (ko) 2019-05-20 2022-01-25 노파르티스 아게 친수성 기를 포함하는 링커를 갖는 항체 약물 콘쥬게이트
KR20220010535A (ko) 2019-05-21 2022-01-25 브리스톨-마이어스 스큅 컴퍼니 면역조정제
MX2021015501A (es) 2019-07-03 2022-04-20 Oxford Biotherapeutics Ltd Anticuerpos y metodos de uso.
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
JP2022540904A (ja) 2019-07-15 2022-09-20 ブリストル－マイヤーズ スクイブ カンパニー ヒトｔｒｅｍ－１に対する抗体およびその使用
WO2021011678A1 (en) 2019-07-15 2021-01-21 Bristol-Myers Squibb Company Anti-trem-1 antibodies and uses thereof
WO2021087056A1 (en) 2019-10-30 2021-05-06 Bristol-Myers Squibb Company Immunomodulators
EP4061818B1 (de) 2019-11-19 2023-12-06 Bristol-Myers Squibb Company Makrozyklische peptide als pd-l1 inhibitoren und immunomodulatoren zur behandlung von krebs und infektionserkrankungen
KR20220122751A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 암 및 감염성 질환의 치료를 위한 pd-l1 억제제 및 면역조정제로서의 마크로시클릭 펩티드
KR20220122752A (ko) 2020-01-06 2022-09-02 브리스톨-마이어스 스큅 컴퍼니 면역조정제
BR112022017174A2 (pt) 2020-02-27 2022-10-18 Chia Tai Tianqing Pharmaceutical Group Co Ltd Anticorpo monoclonal isolado, ou uma porção de ligação ao antígeno do mesmo, nucleotídeo, vetor de expressão, célula hospedeira, composição farmacêutica e métodos de tratamento de uma doença alérgica e de um tumor
JP2023515633A (ja) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー 放射性標識されたフィブロネクチンに基づく足場および抗体ならびにそのセラノスティクス的使用
EP4118118A1 (de) 2020-03-09 2023-01-18 Bristol-Myers Squibb Company Antikörper gegen cd40 mit verbesserter agonistenaktivität
US20230183292A1 (en) 2020-03-16 2023-06-15 Bristol-Myers Squibb Company Immunomodulators
US20230151059A1 (en) 2020-03-30 2023-05-18 Bristol-Myers Squibb Company Immunomodulators
CA3170570A1 (en) 2020-04-01 2021-10-07 James J. KOBIE Monoclonal antibodies against the hemagglutinin (ha) and neuraminidase (na) of influenza h3n2 viruses
US20230272056A1 (en) 2020-04-09 2023-08-31 Merck Sharp & Dohme Llc Affinity matured anti-lap antibodies and uses thereof
EP3901151A1 (de) 2020-04-21 2021-10-27 iOmx Therapeutics AG Halogenierte heteroaryl- und andere heterocyclische kinaseinhibitoren und verwendungen davon
IL297714A (en) 2020-04-28 2022-12-01 Iomx Therapeutics Ag Bicyclic kinase inhibitors and their uses
KR20230002261A (ko) 2020-04-28 2023-01-05 더 락커펠러 유니버시티 항-sars-cov-2 중화 항체 및 이의 사용 방법
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP2023523760A (ja) 2020-05-01 2023-06-07 ノバルティス アーゲー 免疫グロブリン変異体
EP4143236A1 (de) 2020-05-01 2023-03-08 Novartis AG Manipulierte immunglobuline
JP2023524813A (ja) 2020-05-08 2023-06-13 ブリストル－マイヤーズ スクイブ カンパニー 免疫調節剤
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
MX2023001625A (es) 2020-08-07 2023-05-16 Fortis Therapeutics Inc Inmunoconjugados que se dirigen a cd46 y metodos de uso de los mismos.
GB2614162A (en) 2020-09-09 2023-06-28 Social Profit Network Methods and compositions for delivery of biotin to mitochondria
WO2022072797A1 (en) 2020-10-02 2022-04-07 Bristol-Myers Squibb Company Macrocyclic peptide boronate immunomodulators
JP2023546020A (ja) 2020-10-08 2023-11-01 ブリストル－マイヤーズ スクイブ カンパニー 新規二量体免疫調節剤
CN116323640A (zh) 2020-10-09 2023-06-23 百时美施贵宝公司 大环免疫调节剂
EP4240758A1 (de) 2020-11-04 2023-09-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
IL302569A (en) 2020-11-06 2023-07-01 Novartis Ag CD19 binding molecules and their uses
WO2022097061A1 (en) 2020-11-06 2022-05-12 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
US20230399403A1 (en) 2020-11-11 2023-12-14 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
CN114685669A (zh) 2020-12-30 2022-07-01 和铂医药(苏州)有限公司 结合trop2的抗体及其用途
US20220227844A1 (en) 2021-01-15 2022-07-21 The Rockefeller University Neutralizing anti-sars-cov-2 antibodies
CN117157306A (zh) 2021-03-24 2023-12-01 百时美施贵宝公司 免疫调节剂
EP4320159A1 (de) 2021-04-09 2024-02-14 Celldex Therapeutics, Inc. Antikörper gegen ilt4, bispezifische anti-ilt4/pd-l1-antikörper und verwendungen davon
KR20230169230A (ko) 2021-04-12 2023-12-15 브리스톨-마이어스 스큅 컴퍼니 시클릭 펩티드 면역조정제
KR20240054417A (ko) 2021-04-16 2024-04-25 노파르티스 아게 항체 약물 접합체 및 이의 제조 방법
AU2022261124A1 (en) 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
EP4334343A2 (de) 2021-05-06 2024-03-13 The Rockefeller University Neutralisierende anti-sars-cov-2-antikörper und verfahren zur verwendung davon
BR112023023831A2 (pt) 2021-05-26 2024-01-30 Oxford Biotherapeutics Ltd Métodos, combinação farmacêutica, anticorpo ou porção de ligação ao antígeno do mesmo
EP4351553A1 (de) 2021-06-09 2024-04-17 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt GmbH Neue antifibrotische arzneimittel
WO2022261161A1 (en) 2021-06-09 2022-12-15 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
EP4370530A1 (de) 2021-07-12 2024-05-22 Bristol-Myers Squibb Company Makrocyclische immunomodulatoren
KR20240035843A (ko) 2021-07-19 2024-03-18 브리스톨-마이어스 스큅 컴퍼니 마크로시클릭 면역조정제
CN113773401B (zh) 2021-09-15 2023-06-20 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和pd-l1的重组融合蛋白及其制备和用途
CN113956363B (zh) 2021-10-13 2023-03-31 宜明昂科生物医药技术（上海）股份有限公司 靶向cd47和cd24的重组融合蛋白及其制备和用途
WO2023061005A1 (zh) 2021-10-14 2023-04-20 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
WO2023069994A1 (en) 2021-10-20 2023-04-27 Bristol-Myers Squibb Company Immunomodulators
WO2023073599A1 (en) 2021-10-28 2023-05-04 Novartis Ag Engineered fc variants
WO2023077521A1 (en) 2021-11-08 2023-05-11 Celldex Therapeutics, Inc Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023089314A1 (en) 2021-11-18 2023-05-25 Oxford Biotherapeutics Limited Pharmaceutical combinations
WO2023102507A1 (en) 2021-12-03 2023-06-08 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2023147399A1 (en) 2022-01-27 2023-08-03 The Rockefeller University Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
WO2023192873A1 (en) 2022-03-28 2023-10-05 Bristol-Myers Squibb Company Macrocyclic immunomodulators
EP4257132A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Sik3-inhibitoren zum behandeln von krankheiten, die gegen death-rezeptor -signaltransduktion resistent sind
EP4257609A1 (de) 2022-04-08 2023-10-11 iOmx Therapeutics AG Kombinationstherapien basierend auf pd-1-inhibitoren und sik3-inhibitoren
WO2023209568A1 (en) 2022-04-26 2023-11-02 Novartis Ag Multispecific antibodies targeting il-13 and il-18
US11932693B2 (en) 2022-05-12 2024-03-19 BioNTech SE Monoclonal antibodies directed against programmed death-1 protein and their use in medicine
WO2023225661A1 (en) 2022-05-20 2023-11-23 Bristol-Myers Squibb Company Macrocyclic immunomodulators
WO2024059472A1 (en) 2022-09-12 2024-03-21 Bristol-Myers Squibb Company Macrocyclic immunomodulators
US20240101691A1 (en) 2022-09-21 2024-03-28 Sanofi Biotechnology Humanized anti-il-1r3 antibody and methods of use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136159A (en) * 1977-02-28 1979-01-23 New England Nuclear Corporation Radioassay of folates
JPS57186492A (en) * 1981-04-17 1982-11-16 Kyowa Hakko Kogyo Co Ltd Transformation of bacterium
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
EP0273085A1 (de) * 1986-12-29 1988-07-06 IntraCel Corporation Verfahren zur Einführung fremder Nukleinsäuren in eukaryotische Zellen
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
US5108921A (en) * 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647676B2 (en) 2004-07-23 2020-05-12 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10500204B2 (en) 2007-06-25 2019-12-10 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10738086B2 (en) 2007-06-25 2020-08-11 Endocyte Inc. Conjugates containing hydrophilic spacer linkers
US10765756B2 (en) 2012-02-24 2020-09-08 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US11344623B2 (en) 2012-02-24 2022-05-31 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy

Also Published As

Publication number Publication date
JP3232347B2 (ja) 2001-11-26
ES2113346T3 (es) 1998-05-01
PT93646A (pt) 1990-11-20
ATE160583T1 (de) 1997-12-15
US5820847A (en) 1998-10-13
IE81171B1 (en) 2000-05-31
DE69031763T2 (de) 1998-06-25
EP0466816A1 (de) 1992-01-22
US5635382A (en) 1997-06-03
IL93983A0 (en) 1991-01-31
CA2013582A1 (en) 1990-10-03
CA2013580A1 (en) 1990-10-03
AU5437590A (en) 1990-11-05
CA2013582C (en) 2007-06-19
DK0466816T3 (da) 1998-08-10
IE901201A1 (en) 1991-10-09
JPH05502787A (ja) 1993-05-20
DE69031763D1 (de) 1998-01-08
EP0466816B1 (de) 1997-11-26
EP0466816A4 (en) 1992-05-20
US5416016A (en) 1995-05-16
US5108921A (en) 1992-04-28
WO1990012096A1 (en) 1990-10-18

Similar Documents

Publication Publication Date Title
IL93983A (en) Method for enhanced transmembrane transport of exogenous molecules
ATE17349T1 (de) Neue trisubstituierte imidazolderivate, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische praeparate und ihre verwendung.
DE69226197D1 (de) Hämoglobine als arzneimittelabgabesystem
HK129393A (en) Use of gamma-linolenic acid and related compounds for the manufacture of a medicament for the treatment of complications of diabetes mellitus
DE3481612D1 (de) Gewisse 3-amino-1-benzazepin-2-on-1-alkansaeuren, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
EP0329184A3 (de) Antimere und antimere Konjugation
DE220143T1 (de) Pharmazeutische zubereitungen von metoprolol mit kontrollierter wirkstoff abgabe, verfahren zu ihrer herstellung und verwendung dieser zubereitungen.
GR1001503B (el) Μέ?οδος δια την παρασκευή φαρμακευτικών ενώσεων αι οποίαι περιέχουν ως δραστική ουσία καρβονικά οξέα τα οποία περιέχουν ?είον κα?ώς και η χρησιμοποίησις αυτών δια την καταπολέμησιν των ρετροιών.
DE3868076D1 (de) Heterocyclische derivate, verfahren zu ihrer herstellung und diese derivate als aktive bestandteile enthaltende fungizide.
GR3035544T3 (en) Microparticle delivery system
HUT45021A (en) Process for production of insecticides and acaricides containing pirasoline-derivatives as active substance and process for production of the active substances
AU2415888A (en) A method for preventing blood coaguli from being formed in the extra-body circuit of dialysis apparatus and composition useful therefor
DE3881950D1 (de) Azabicyclische verbindungen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
TW261615B (de)
ZA87472B (en) System for delivering drug with enhanced bioacceptability
NO175040C (de)
EP0327709A3 (de) Platin-Komplex, diesen enthaltendes antineoplastisches Agens, Zwischenprodukt, Verfahren zur Herstellung und Verwendung
EP0289572A4 (de) Verwendung von interleukin-1-proteinen gegen arthritis.
KR840006492A (ko) 플라티늄-디아민 착화물의 제조 방법
GR3005743T3 (de)
HU905897D0 (en) Process for the production of complexed medical preparations from ionogenic active agents
ES8705763A1 (es) Procedimiento para preparar nuevas formulaciones de gel parafines terapeuticos y diagnosticos
ES465180A1 (es) Procedimiento para la preparacion de preparados de inmuno- globulinas
DE3481418D1 (de) Substituierte spiropyridinderivate, diese enthaltende pharmazeutische zubereitungen, verfahren zu ihrer herstellung und zubereitungen.
ES8504166A1 (es) Un metodo de preparar derivados de 6,11-dihidrodibenz(b,e) oxepina.

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
EXP Patent expired